<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XELODA - capecitabine tablet, film coated </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<h1>XELODA<span class="Sup">®</span><br> (capecitabine)<br> TABLETS</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOXED"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First">XELODA Warfarin Interaction: Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) monitored frequently in order to adjust the anticoagulant dose accordingly. A clinically important XELODA-Warfarin drug interaction was demonstrated in a clinical pharmacology trial (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>). Altered coagulation parameters and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Postmarketing reports have shown clinically significant increases in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and INR in patients who were stabilized on anticoagulants at the time XELODA was introduced. These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within 1 month after stopping XELODA. These events occurred in patients with and without liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">XELODA (capecitabine) is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to 5-fluorouracil.</p>
<p>The chemical name for capecitabine is 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine and has a molecular weight of 359.35. Capecitabine has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-01.jpg"></p>
<p>Capecitabine is a white to off-white crystalline powder with an aqueous solubility of 26 mg/mL at 20°C.</p>
<p>XELODA is supplied as biconvex, oblong film-coated tablets for oral administration. Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. The inactive ingredients in XELODA include: anhydrous lactose, croscarmellose sodium, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium stearate and purified water. The peach or light peach film coating contains hydroxypropyl methylcellulose, talc, titanium dioxide, and synthetic yellow and red iron oxides.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">XELODA is relatively non-cytotoxic in vitro. This drug is enzymatically converted to 5-fluorouracil (5-FU) in vivo.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Bioactivation</h2>
<p class="First">Capecitabine is readily absorbed from the gastrointestinal tract. In the liver, a 60 kDa carboxylesterase hydrolyzes much of the compound to 5'-deoxy-5-fluorocytidine (5'-DFCR). Cytidine deaminase, an enzyme found in most tissues, including tumors, subsequently converts 5'-DFCR to 5'-deoxy-5-fluorouridine (5'-DFUR). The enzyme, thymidine phosphorylase (dThdPase), then hydrolyzes 5'-DFUR to the active drug 5-FU. Many tissues throughout the body express thymidine phosphorylase. Some human carcinomas express this enzyme in higher concentrations than surrounding normal tissues.</p>
<p><span class="Bold">Metabolic Pathway of capecitabine to 5-FU</span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N<span class="Sup">5-10</span>-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics in Colorectal Tumors and Adjacent Healthy Tissue</h2>
<p class="First">Following oral administration of XELODA 7 days before surgery in patients with colorectal cancer, the median ratio of 5-FU concentration in colorectal tumors to adjacent tissues was 2.9 (range from 0.9 to 8.0). These ratios have not been evaluated in breast cancer patients or compared to 5-FU infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>Human Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of XELODA and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg/m<span class="Sup">2</span>/day. Over this range, the pharmacokinetics of XELODA and its metabolite, 5'-DFCR were dose proportional and did not change over time. The increases in the AUCs of 5'-DFUR and 5-FU, however, were greater than proportional to the increase in dose and the AUC of 5-FU was 34% higher on day 14 than on day 1. The elimination half-life of both parent capecitabine and 5-FU was about ¾ of an hour. The inter-patient variability in the C<span class="Sub">max</span> and AUC of 5-FU was greater than 85%.</p>
<p>Following oral administration of 825 mg/m<span class="Sup">2</span> capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower C<span class="Sub">max</span> and 24% lower AUC for capecitabine than the Caucasian patients (n=22). Japanese patients had also about 25% lower C<span class="Sub">max</span> and 34% lower AUC for FBAL than the Caucasian patients. The clinical significance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5'-DFCR, 5'-DFUR, and 5-FU).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.5"></a><p></p>
<h2>Absorption, Distribution, Metabolism and Excretion</h2>
<p class="First">Capecitabine reached peak blood levels in about 1.5 hours (T<span class="Sub">max</span>) with peak 5-FU levels occurring slightly later, at 2 hours. Food reduced both the rate and extent of absorption of capecitabine with mean C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span> decreased by 60% and 35%, respectively. The C<span class="Sub">max</span> and AUC<span class="Sub">0-∞</span> of 5-FU were also reduced by food by 43% and 21%, respectively. Food delayed T<span class="Sub">max</span> of both parent and 5-FU by 1.5 hours (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span> and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). </p>
<p>Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent. Capecitabine was primarily bound to human albumin (approximately 35%).</p>
<p>Capecitabine is extensively metabolized enzymatically to 5-FU. The enzyme dihydropyrimidine dehydrogenase hydrogenates 5-FU, the product of capecitabine metabolism, to the much less toxic 5-fluoro-5, 6-dihydro-fluorouracil (FUH<span class="Sub">2</span>). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureido-propionic acid (FUPA). Finally, β-ureido-propionase cleaves FUPA to α-fluoro-β-alanine (FBAL) which is cleared in the urine.</p>
<p>Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose. About 3% of the administered dose is excreted in urine as unchanged drug.</p>
<p>A clinical phase 1 study evaluating the effect of XELODA on the pharmacokinetics of docetaxel (Taxotere®) and the effect of docetaxel on the pharmacokinetics of XELODA was conducted in 26 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. XELODA was found to have no effect on the pharmacokinetics of docetaxel (C<span class="Sub">max</span> and AUC) and docetaxel has no effect on the pharmacokinetics of capecitabine and the 5-FU precursor 5'-DFUR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="C_special"></a><a name="section-2.6"></a><p></p>
<h2>Special Populations</h2>
<p class="First">A population analysis of pooled data from the two large controlled studies in patients with metastatic colorectal cancer (n=505) who were administered XELODA at 1250 mg/m<span class="Sup">2</span> twice a day indicated that gender (202 females and 303 males) and race (455 white/Caucasian patients, 22 black patients, and 28 patients of other race) have no influence on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL. Age has no significant influence on the pharmacokinetics of 5'-DFUR and 5-FU over the range of 27 to 86 years. A 20% increase in age results in a 15% increase in AUC of FBAL (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span> and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">XELODA has been evaluated in 13 patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> defined by a composite score including bilirubin, AST/ALT and alkaline phosphatase following a single 1255 mg/m<span class="Sup">2</span> dose of XELODA. Both AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> of capecitabine increased by 60% in patients with hepatic dysfunction compared to patients with normal hepatic function (n=14). The AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> of 5-FU were not affected. In patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, caution should be exercised when XELODA is administered. The effect of severe hepatic dysfunction on XELODA is not known (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span> and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">Following oral administration of 1250 mg/m<span class="Sup">2</span> capecitabine twice a day to cancer patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, patients with moderate (creatinine clearance = 30 to 50 mL/min) and severe (creatinine clearance &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> showed 85% and 258% higher systemic exposure to FBAL on day 1 compared to normal renal function patients (creatinine clearance &gt;80 mL/min). Systemic exposure to 5'-DFUR was 42% and 71% greater in moderately and severely renal impaired patients, respectively, than in normal patients. Systemic exposure to capecitabine was about 25% greater in both moderately and severely renal impaired patients (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>, <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>, and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.9"></a><p></p>
<h2>Drug-Drug Interactions</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.10"></a><p></p>
<h2>Anticoagulants</h2>
<p class="First">In four patients with cancer, chronic administration of capecitabine (1250 mg/m<span class="Sup">2 </span>bid) with a single 20 mg dose of warfarin increased the mean AUC of S-warfarin by 57% and decreased its clearance by 37%. Baseline corrected AUC of INR in these 4 patients increased by 2.8-fold, and the maximum observed mean INR value was increased by 91% (see <span class="Bold"><a href="#BOXED">Boxed WARNING</a></span> and <span class="Bold"><a href="#P_drug">PRECAUTIONS: Drug-Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.11"></a><p></p>
<h2>Drugs Metabolized by Cytochrome P450 Enzymes</h2>
<p class="First">In vitro enzymatic studies with human liver microsomes indicated that capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5-FU, and FBAL) had no inhibitory effects on substrates of cytochrome P450 for the major isoenzymes such as 1A2, 2A6, 3A4, 2C9, 2C19, 2D6, and 2E1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.12"></a><p></p>
<h2>Antacid</h2>
<p class="First">When Maalox® (20 mL), an aluminum hydroxide- and magnesium hydroxide-containing antacid, was administered immediately after XELODA (1250 mg/m<span class="Sup">2</span>, n=12 cancer patients), AUC and C<span class="Sub">max</span> increased by 16% and 35%, respectively, for capecitabine and by 18% and 22%, respectively, for 5'-DFCR. No effect was observed on the other three major metabolites (5'-DFUR, 5-FU, FBAL) of XELODA.</p>
<p>XELODA has a low potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> related to plasma protein binding.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="C_STUDIES"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>General</h2>
<p class="First">The recommended dose of XELODA was determined in an open-label, randomized clinical study, exploring the efficacy and safety of continuous therapy with capecitabine (1331 mg/m<span class="Sup">2</span>/day in two divided doses, n=39), intermittent therapy with capecitabine (2510 mg/m<span class="Sup">2</span>/day in two divided doses, n=34), and intermittent therapy with capecitabine in combination with oral leucovorin (LV) (capecitabine 1657 mg/m<span class="Sup">2</span>/day in two divided doses, n=35; leucovorin 60 mg/day) in patients with advanced and/or metastatic colorectal carcinoma in the first-line metastatic setting. There was no apparent advantage in response rate to adding leucovorin to XELODA; however, toxicity was increased. XELODA, 1250 mg/m<span class="Sup">2</span> twice daily for 14 days followed by a 1-week rest, was selected for further clinical development based on the overall safety and efficacy profile of the three schedules studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Adjuvant Colon Cancer</h2>
<p class="First">A multicenter randomized, controlled phase 3 clinical trial in patients with Dukes' C colon cancer provided data concerning the use of XELODA for the adjuvant treatment of patients with colon cancer. The primary objective of the study was to compare disease-free survival (DFS) in patients receiving XELODA to those receiving IV 5-FU/LV alone. In this trial, 1987 patients were randomized either to treatment with XELODA 1250 mg/m<span class="Sup">2</span> orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks) or IV bolus 5-FU 425 mg/m<span class="Sup">2</span> and 20 mg/m<span class="Sup">2</span> IV leucovorin on days 1 to 5, given as 4-week cycles for a total of 6 cycles (24 weeks). Patients in the study were required to be between 18 and 75 years of age with histologically-confirmed Dukes' stage C colon cancer with at least one positive lymph node and to have undergone (within 8 weeks prior to randomization) complete resection of the primary tumor without macroscopic or microscopic evidence of remaining tumor. Patients were also required to have no prior cytotoxic chemotherapy or immunotherapy (except steroids), and have an ECOG performance status of 0 or 1 (KPS ≥ 70%), ANC ≥ 1.5×10<span class="Sup">9</span>/L, platelets ≥ 100×10<span class="Sup">9</span>/L, serum creatinine ≤ 1.5 ULN, total bilirubin ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN and CEA within normal limits at time of randomization.</p>
<p>The baseline demographics for XELODA and 5-FU/LV patients are shown in <span class="Bold"><a href="#t1">Table 1</a></span>. The baseline characteristics were well-balanced between arms. </p>
<a name="t1"></a><table width="75%">
<caption><span>Table 1 Baseline Demographics</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">XELODA<br>(n=1004)</th>
<th class="Lrule Rrule" align="center">5-FU/LV<br>(n=983)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Age (median, years)</td>
<td class="Lrule" align="center">62</td>
<td class="Lrule Rrule" align="center">63</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Range</td>
<td class="Botrule Lrule" align="center">(25-80)</td>
<td class="Botrule Lrule Rrule" align="center">(22-82)</td>
</tr>
<tr>
<td class="Lrule" align="left">Gender</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Male (n, %)</td>
<td class="Lrule" align="center">542 (54)</td>
<td class="Lrule Rrule" align="center">532 (54)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Female (n, %)</td>
<td class="Botrule Lrule" align="center">461 (46)</td>
<td class="Botrule Lrule Rrule" align="center">451 (46)</td>
</tr>
<tr>
<td class="Lrule" align="left">ECOG PS</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  0 (n, %)</td>
<td class="Lrule" align="center">849 (85)</td>
<td class="Lrule Rrule" align="center">830 (85)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  1 (n, %)</td>
<td class="Botrule Lrule" align="center">152 (15)</td>
<td class="Botrule Lrule Rrule" align="center">147 (15)</td>
</tr>
<tr>
<td class="Lrule" align="left">Staging – Primary Tumor</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  PT1 (n, %)</td>
<td class="Lrule" align="center">12 (1)</td>
<td class="Lrule Rrule" align="center">6 (0.6)</td>
</tr>
<tr>
<td class="Lrule" align="left">  PT2 (n, %)</td>
<td class="Lrule" align="center">90 (9)</td>
<td class="Lrule Rrule" align="center">92 (9)</td>
</tr>
<tr>
<td class="Lrule" align="left">  PT3 (n, %)</td>
<td class="Lrule" align="center">763 (76)</td>
<td class="Lrule Rrule" align="center">746 (76)</td>
</tr>
<tr>
<td class="Lrule" align="left">  PT4 (n, %)</td>
<td class="Lrule" align="center">138 (14)</td>
<td class="Lrule Rrule" align="center">139 (14)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Other (n, %)</td>
<td class="Botrule Lrule" align="center">1 (0.1)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Lrule" align="left">Staging – Lymph Node</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  pN1 (n, %)</td>
<td class="Lrule" align="center">695 (69)</td>
<td class="Lrule Rrule" align="center">694 (71)</td>
</tr>
<tr>
<td class="Lrule" align="left">  pN2 (n, %)</td>
<td class="Lrule" align="center">305 (30)</td>
<td class="Lrule Rrule" align="center">288 (29)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">  Other (n, %)</td>
<td class="Botrule Lrule" align="center">4 (0.4)</td>
<td class="Botrule Lrule Rrule" align="center">1 (0.1)</td>
</tr>
</tbody>
</table>
<p>All patients with normal renal function or mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> began treatment at the full starting dose of 1250 mg/m<span class="Sup">2</span> orally twice daily. The starting dose was reduced in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (calculated creatinine clearance 30 to 50 mL/min) at baseline (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). Subsequently, for all patients, doses were adjusted when needed according to toxicity. Dose management for XELODA included dose reductions, cycle delays and treatment interruptions (see <span class="Bold"><a href="#t2">Table 2</a></span>).</p>
<a name="t2"></a><table width="75%">
<caption><span>Table 2 Summary of Dose Modifications in X-ACT Study</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">XELODA<br>N = 995</th>
<th class="Lrule Rrule" align="center">5-FU/LV<br>N = 974</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">Median relative dose intensity (%)</td>
<td class="Botrule Lrule" align="center">93</td>
<td class="Botrule Lrule Rrule" align="center">92</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients completing full course of treatment (%)</td>
<td class="Botrule Lrule" align="center">83</td>
<td class="Botrule Lrule Rrule" align="center">87</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients with treatment interruption (%)</td>
<td class="Botrule Lrule" align="center">15</td>
<td class="Botrule Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients with cycle delay (%)</td>
<td class="Botrule Lrule" align="center">46</td>
<td class="Botrule Lrule Rrule" align="center">29</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients with dose reduction (%)</td>
<td class="Botrule Lrule" align="center">42</td>
<td class="Botrule Lrule Rrule" align="center">44</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">Patients with treatment interruption, cycle delay, or dose reduction (%)</td>
<td class="Botrule Lrule" align="center">57</td>
<td class="Botrule Lrule Rrule" align="center">52</td>
</tr>
</tbody>
</table>
<p>The median follow-up at the time of the analysis was 53 months. The hazard ratio for DFS for XELODA compared to 5-FU/LV was 0.87 (95% C.I. 0.76 – 1.00). Because the upper 2-sided 95% confidence limit of hazard ratio was less than 1.20, XELODA was non-inferior to 5-FU/LV. The choice of the non-inferiority margin of 1.20 corresponds to the retention of approximately 75% of the 5-FU/LV effect on DFS. </p>
<p>Survival data were not mature at the time of the analysis with a median follow-up of 53 months. The comparison of overall survival did not reach statistical significance for the test of difference (HR 0.88, 95% C.I. 0.74 – 1.05; p = 0.169).</p>
<table width="75%">
<caption><span>Table 3 Efficacy of XELODA vs 5-FU/LV in Adjuvant Treatment of Colon Cancer<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"><span class="Italics">All Randomized Population</span></th>
<th class="Lrule" align="center">XELODA<br>(n=1004)</th>
<th class="Lrule Rrule" align="center">5-FU/LV<br>(n=983)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Approximately 85% had 3-year DFS information</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Log-rank test for differences of XELODA vs 5-FU/LV</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="Bold">Median follow-up (months)</span></td>
<td class="Botrule Lrule" align="center">53</td>
<td class="Botrule Lrule Rrule" align="center">53</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">3-year Disease-free Survival Rates</span></td>
<td class="Botrule Lrule" align="center" valign="bottom">66.0</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">62.9</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">Hazard Ratio<br>(XELODA/5-FU/LV)<br>(95% C.I. for Hazard Ratio),<br>p-value<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="bottom">0.87<br>(0.76 – 1.00)<br>p = 0.055</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 1 Kaplan-Meier Estimates of Disease-Free Survival (All Randomized Population)<a name="footnote-reference-3" href="#footnote-3" class="Sup">1</a></span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-03.jpg"></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">1</a></dt>
<dd><span class="Bold">XELODA has been demonstrated to be non-inferior to 5-FU/LV.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Metastatic Colorectal Cancer</h2>
<p class="First">Data from two open-label, multicenter, randomized, controlled clinical trials involving 1207 patients support the use of XELODA in the first-line treatment of patients with metastatic colorectal carcinoma. The two clinical studies were identical in design and were conducted in 120 centers in different countries. Study 1 was conducted in the US, Canada, Mexico, and Brazil; Study 2 was conducted in Europe, Israel, Australia, New Zealand, and Taiwan. Altogether, in both trials, 603 patients were randomized to treatment with XELODA at a dose of 1250 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles; 604 patients were randomized to treatment with 5-FU and leucovorin (20 mg/m<span class="Sup">2</span> leucovorin IV followed by 425 mg/m<span class="Sup">2</span> IV bolus 5-FU, on days 1 to 5, every 28 days).</p>
<p>In both trials, overall survival, time to progression and response rate (complete plus partial responses) were assessed. Responses were defined by the World Health Organization criteria and submitted to a blinded independent review committee (IRC). Differences in assessments between the investigator and IRC were reconciled by the sponsor, blinded to treatment arm, according to a specified algorithm. Survival was assessed based on a non-inferiority analysis.</p>
<p>The baseline demographics for XELODA and 5-FU/LV patients are shown in <span class="Bold"><a href="#t4">Table 4</a></span>.</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4 Baseline Demographics of Controlled Colorectal Trials</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="2">Study 1</th>
<th class="Lrule Rrule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left"></th>
<th class="Lrule Toprule" align="center">XELODA<br>(n=302)</th>
<th class="Lrule Toprule" align="center">5-FU/LV<br>(n=303)</th>
<th class="Lrule Toprule" align="center">XELODA<br>(n=301)</th>
<th class="Lrule Rrule Toprule" align="center">5-FU/LV<br>(n=301)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Age (median, years)</td>
<td class="Lrule" align="center">64</td>
<td class="Lrule" align="center">63</td>
<td class="Lrule" align="center">64</td>
<td class="Lrule Rrule" align="center">64</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Range</td>
<td class="Botrule Lrule" align="center">(23-86)</td>
<td class="Botrule Lrule" align="center">(24-87)</td>
<td class="Botrule Lrule" align="center">(29-84)</td>
<td class="Botrule Lrule Rrule" align="center">(36-86)</td>
</tr>
<tr>
<td class="Lrule" align="left">Gender</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Male (%)</td>
<td class="Lrule" align="center">181 (60)</td>
<td class="Lrule" align="center">197 (65)</td>
<td class="Lrule" align="center">172 (57)</td>
<td class="Lrule Rrule" align="center">173 (57)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Female (%)</td>
<td class="Botrule Lrule" align="center">121 (40)</td>
<td class="Botrule Lrule" align="center">106 (35)</td>
<td class="Botrule Lrule" align="center">129 (43)</td>
<td class="Botrule Lrule Rrule" align="center">128 (43)</td>
</tr>
<tr>
<td class="Lrule" align="left">Karnofsky PS (median)</td>
<td class="Lrule" align="center">90</td>
<td class="Lrule" align="center">90</td>
<td class="Lrule" align="center">90</td>
<td class="Lrule Rrule" align="center">90</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Range</td>
<td class="Botrule Lrule" align="center">(70-100)</td>
<td class="Botrule Lrule" align="center">(70-100)</td>
<td class="Botrule Lrule" align="center">(70-100)</td>
<td class="Botrule Lrule Rrule" align="center">(70-100)</td>
</tr>
<tr>
<td class="Lrule" align="left">Colon (%)</td>
<td class="Lrule" align="center">222 (74)</td>
<td class="Lrule" align="center">232 (77)</td>
<td class="Lrule" align="center">199 (66)</td>
<td class="Lrule Rrule" align="center">196 (65)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Rectum (%)</td>
<td class="Botrule Lrule" align="center">79 (26)</td>
<td class="Botrule Lrule" align="center">70 (23)</td>
<td class="Botrule Lrule" align="center">101 (34)</td>
<td class="Botrule Lrule Rrule" align="center">105 (35)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Prior radiation therapy (%)</td>
<td class="Botrule Lrule" align="center">52 (17)</td>
<td class="Botrule Lrule" align="center">62 (21)</td>
<td class="Botrule Lrule" align="center">42 (14)</td>
<td class="Botrule Lrule Rrule" align="center">42 (14)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">Prior adjuvant 5-FU (%)</td>
<td class="Botrule Lrule" align="center">84 (28)</td>
<td class="Botrule Lrule" align="center">110 (36)</td>
<td class="Botrule Lrule" align="center">56 (19)</td>
<td class="Botrule Lrule Rrule" align="center">41 (14)</td>
</tr>
</tbody>
</table>
<p>The efficacy endpoints for the two phase 3 trials are shown in <span class="Bold"><a href="#t5">Table 5</a></span> and <span class="Bold"><a href="#t6">Table 6</a></span>.</p>
<a name="t5"></a><table width="75%">
<caption><span>Table 5 Efficacy of XELODA vs 5-FU/LV in Colorectal Cancer (Study 1)</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">XELODA<br>(n=302)</th>
<th class="Lrule Rrule" align="center">5-FU/LV<br>(n=303)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Overall Response Rate</span></td>
<td class="Lrule" align="center" valign="bottom"></td>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(%, 95% C.I.)</td>
<td class="Botrule Lrule" align="center" valign="bottom">21 (16-26)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">11 (8-15)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(<span class="Italics">p</span>-value)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">0.0014</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Time to Progression</span></td>
<td class="Lrule" align="center" valign="bottom"></td>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(Median, days, 95% C.I.)</td>
<td class="Botrule Lrule" align="center" valign="bottom">128 (120-136)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">131 (105-153)</td>
</tr>
<tr>
<td class="Lrule" align="left">Hazard Ratio (XELODA/5-FU/LV)</td>
<td class="Lrule Rrule" align="center" colspan="2">0.99</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">95% C.I. for Hazard Ratio</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(0.84-1.17)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Survival</span></td>
<td class="Lrule" align="center" valign="bottom"></td>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(Median, days, 95% C.I.)</td>
<td class="Botrule Lrule" align="center" valign="bottom">380 (321-434)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">407 (366-446)</td>
</tr>
<tr>
<td class="Lrule" align="left">Hazard Ratio (XELODA/5-FU/LV)</td>
<td class="Lrule Rrule" align="center" colspan="2">1.00</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">95% C.I. for Hazard Ratio</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(0.84-1.18)</td>
</tr>
</tbody>
</table>
<a name="t6"></a><table width="75%">
<caption><span>Table 6 Efficacy of XELODA vs 5-FU/LV in Colorectal Cancer (Study 2)</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">XELODA<br>(n=301)</th>
<th class="Lrule Rrule" align="center">5-FU/LV<br>(n=301)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Overall Response Rate</span></td>
<td class="Lrule" align="center" valign="bottom"></td>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(%, 95% C.I.)</td>
<td class="Botrule Lrule" align="center" valign="bottom">21 (16-26)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">14 (10-18)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(<span class="Italics">p</span>-value)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">0.027</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Time to Progression</span></td>
<td class="Lrule" align="center" valign="bottom"></td>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(Median, days, 95% C.I.)</td>
<td class="Botrule Lrule" align="center" valign="bottom">137 (128-165)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">131 (102-156)</td>
</tr>
<tr>
<td class="Lrule" align="left">Hazard Ratio (XELODA/5-FU/LV)</td>
<td class="Lrule Rrule" align="center" colspan="2">0.97</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">95% C.I. for Hazard Ratio</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(0.82-1.14)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Survival</span></td>
<td class="Lrule" align="center" valign="bottom"></td>
<td class="Lrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">(Median, days, 95% C.I.)</td>
<td class="Botrule Lrule" align="center" valign="bottom">404 (367-452)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">369 (338-430)</td>
</tr>
<tr>
<td class="Lrule" align="left">Hazard Ratio (XELODA/5-FU/LV)</td>
<td class="Lrule Rrule" align="center" colspan="2">0.92</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">95% C.I. for Hazard Ratio</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(0.78-1.09)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 2 Kaplan-Meier Curve for Overall Survival of Pooled Data (Studies 1 and 2)</span></p>
<p><a name="f2"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-04.jpg"></p>
<p>XELODA was superior to 5-FU/LV for objective response rate in Study 1 and Study 2. The similarity of XELODA and 5-FU/LV in these studies was assessed by examining the potential difference between the two treatments. In order to assure that XELODA has a clinically meaningful survival effect, statistical analyses were performed to determine the percent of the survival effect of 5-FU/LV that was retained by XELODA. The estimate of the survival effect of 5-FU/LV was derived from a meta-analysis of ten randomized studies from the published literature comparing 5-FU to regimens of 5-FU/LV that were similar to the control arms used in these Studies 1 and 2. The method for comparing the treatments was to examine the worst case (95% confidence upper bound) for the difference between 5-FU/LV and XELODA, and to show that loss of more than 50% of the 5-FU/LV survival effect was ruled out. It was demonstrated that the percent of the survival effect of 5-FU/LV maintained was at least 61% for Study 2 and 10% for Study 1. The pooled result is consistent with a retention of at least 50% of the effect of 5-FU/LV. It should be noted that these values for preserved effect are based on the upper bound of the 5-FU/LV vs XELODA difference. These results do not exclude the possibility of true equivalence of XELODA to 5-FU/LV (see <span class="Bold"><a href="#t5">Table 5</a></span>, <span class="Bold"><a href="#t6">Table 6</a></span>, and <span class="Bold"><a href="#f2">Figure 2</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Breast Cancer</h2>
<p class="First">XELODA has been evaluated in clinical trials in combination with docetaxel (Taxotere®) and as monotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>Breast Cancer Combination Therapy</h2>
<p class="First">The dose of XELODA used in the phase 3 clinical trial in combination with docetaxel was based on the results of a phase 1 study, where a range of doses of docetaxel administered in 3-week cycles in combination with an intermittent regimen of XELODA (14 days of treatment, followed by a 7-day rest period) were evaluated. The combination dose regimen was selected based on the tolerability profile of the 75 mg/m<span class="Sup">2</span> administered in 3-week cycles of docetaxel in combination with 1250 mg/m<span class="Sup">2</span> twice daily for 14 days of XELODA administered in 3-week cycles. The approved dose of 100 mg/m<span class="Sup">2</span> of docetaxel administered in 3-week cycles was the control arm of the phase 3 study.</p>
<p>XELODA in combination with docetaxel was assessed in an open-label, multicenter, randomized trial in 75 centers in Europe, North America, South America, Asia, and Australia. A total of 511 patients with metastatic breast cancer resistant to, or recurring during or after an anthracycline-containing therapy, or relapsing during or recurring within 2 years of completing an anthracycline-containing adjuvant therapy were enrolled. Two hundred and fifty-five (255) patients were randomized to receive XELODA 1250 mg/m<span class="Sup">2</span> twice daily for 14 days followed by 1 week without treatment and docetaxel 75 mg/m<span class="Sup">2</span> as a 1-hour intravenous infusion administered in 3-week cycles. In the monotherapy arm, 256 patients received docetaxel 100 mg/m<span class="Sup">2</span> as a 1-hour intravenous infusion administered in 3-week cycles. Patient demographics are provided in <span class="Bold"><a href="#t7">Table 7</a></span>.</p>
<a name="t7"></a><table width="80%">
<caption><span>Table 7 Baseline Demographics and Clinical Characteristics XELODA and Docetaxel Combination vs Docetaxel in Breast Cancer Trial</span></caption>
<col align="left" valign="bottom" width="50%">
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">XELODA + Docetaxel<br>(n=255)</th>
<th class="Lrule Rrule" align="center">Docetaxel<br>(n=256)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Includes 10 patients in combination and 18 patients in monotherapy arms treated with an anthracenedione</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">
<span class="Bold Italics">Age</span> (median, years)</td>
<td class="Botrule Lrule" align="center">52</td>
<td class="Botrule Lrule Rrule" align="center">51</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">
<span class="Bold Italics">Karnofsky PS</span> (median)</td>
<td class="Botrule Lrule" align="center">90</td>
<td class="Botrule Lrule Rrule" align="center">90</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">Site of Disease</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Lymph nodes</td>
<td class="Lrule" align="center">121 (47%)</td>
<td class="Lrule Rrule" align="center">125 (49%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Liver</td>
<td class="Lrule" align="center">116 (45%)</td>
<td class="Lrule Rrule" align="center">122 (48%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Bone</td>
<td class="Lrule" align="center">107 (42%)</td>
<td class="Lrule Rrule" align="center">119 (46%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Lung</td>
<td class="Lrule" align="center">95 (37%)</td>
<td class="Lrule Rrule" align="center">99 (39%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Skin</td>
<td class="Botrule Lrule" align="center">73 (29%)</td>
<td class="Botrule Lrule Rrule" align="center">73 (29%)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">Prior Chemotherapy</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Anthracycline<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Lrule" align="center">255 (100%)</td>
<td class="Lrule Rrule" align="center">256 (100%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  5-FU</td>
<td class="Lrule" align="center">196 (77%)</td>
<td class="Lrule Rrule" align="center">189 (74%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Paclitaxel</td>
<td class="Botrule Lrule" align="center">25 (10%)</td>
<td class="Botrule Lrule Rrule" align="center">22 (9%)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">Resistance to an Anthracycline</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  No resistance</td>
<td class="Lrule" align="center">19 (7%)</td>
<td class="Lrule Rrule" align="center">19 (7%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Progression on anthracycline therapy</td>
<td class="Lrule" align="center">65 (26%)</td>
<td class="Lrule Rrule" align="center">73 (29%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Stable disease after 4 cycles of anthracycline therapy</td>
<td class="Lrule" align="center" valign="bottom">41 (16%)</td>
<td class="Lrule Rrule" align="center" valign="bottom">40 (16%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Relapsed within 2 years of completion of anthracycline-adjuvant therapy</td>
<td class="Lrule" align="center" valign="bottom">78 (31%)</td>
<td class="Lrule Rrule" align="center" valign="bottom">74 (29%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Experienced a brief response to anthracycline therapy, with subsequent progression while on therapy or within 12 months after last dose</td>
<td class="Botrule Lrule" align="center" valign="bottom">51 (20%)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">50 (20%)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">No. of Prior Chemotherapy Regimens for Treatment of <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic Disease</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  0</td>
<td class="Lrule" align="center">89 (35%)</td>
<td class="Lrule Rrule" align="center">80 (31%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  1</td>
<td class="Lrule" align="center">123 (48%)</td>
<td class="Lrule Rrule" align="center">135 (53%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  2</td>
<td class="Lrule" align="center">43 (17%)</td>
<td class="Lrule Rrule" align="center">39 (15%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">  3</td>
<td class="Botrule Lrule" align="center">0 (0%)</td>
<td class="Botrule Lrule Rrule" align="center">2 (1%)</td>
</tr>
</tbody>
</table>
<p>XELODA in combination with docetaxel resulted in statistically significant improvement in time to disease progression, overall survival and objective response rate compared to monotherapy with docetaxel as shown in <span class="Bold"><a href="#t8">Table 8</a></span>, <span class="Bold"><a href="#f3">Figure 3</a></span>, and <span class="Bold"><a href="#f4">Figure 4</a></span>.</p>
<a name="t8"></a><table width="75%">
<caption><span>Table 8	Efficacy of XELODA and Docetaxel Combination vs Docetaxel Monotherapy</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="19%">
<col align="center" valign="top" width="19%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="19%">
<thead><tr class="First Last">
<th class="Lrule" align="left" valign="top">Efficacy Parameter</th>
<th class="Lrule" align="center">Combination Therapy</th>
<th class="Lrule" align="center" valign="top">Monotherapy</th>
<th class="Lrule" align="center" valign="top">p-value</th>
<th class="Lrule Rrule" align="center">Hazard Ratio</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>The response rate reported represents a reconciliation of the investigator and IRC assessments performed by the sponsor according to a predefined algorithm.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>NA = Not Applicable</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Time to Disease Progression</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">Median Days</span></td>
<td class="Lrule" align="center">186</td>
<td class="Lrule" align="center">128</td>
<td class="Lrule" align="center">0.0001</td>
<td class="Lrule Rrule" align="center">0.643</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><span class="Bold">95% C.I.</span></td>
<td class="Botrule Lrule" align="center">(165-198)</td>
<td class="Botrule Lrule" align="center">(105-136)</td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Overall Survival</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="center"><span class="Bold">Median Days</span></td>
<td class="Lrule" align="center">442</td>
<td class="Lrule" align="center">352</td>
<td class="Lrule" align="center">0.0126</td>
<td class="Lrule Rrule" align="center">0.775</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><span class="Bold">95% C.I.</span></td>
<td class="Botrule Lrule" align="center">(375-497)</td>
<td class="Botrule Lrule" align="center">(298-387)</td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left"><span class="Bold">Response Rate<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></span></td>
<td class="Botrule Lrule" align="center">32%</td>
<td class="Botrule Lrule" align="center">22%</td>
<td class="Botrule Lrule" align="center">0.009</td>
<td class="Botrule Lrule Rrule" align="center">NA<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 3 Kaplan-Meier Estimates for Time to Disease Progression XELODA and Docetaxel vs Docetaxel</span></p>
<p><a name="f3"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-05.jpg"></p>
<p><span class="Bold">Figure 4 Kaplan-Meier Estimates of Survival XELODA and Docetaxel vs Docetaxel</span></p>
<p><a name="f4"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-06.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2>Breast Cancer Monotherapy</h2>
<p class="First">The antitumor activity of XELODA as a monotherapy was evaluated in an open-label single-arm trial conducted in 24 centers in the US and Canada. A total of 162 patients with stage IV breast cancer were enrolled. The primary endpoint was tumor response rate in patients with measurable disease, with response defined as a ≥50% decrease in sum of the products of the perpendicular diameters of bidimensionally measurable disease for at least 1 month. XELODA was administered at a dose of 1255 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles. The baseline demographics and clinical characteristics for all patients (n=162) and those with measurable disease (n=135) are shown in <span class="Bold"><a href="#t9">Table 9</a></span>. Resistance was defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant chemotherapy regimen.</p>
<a name="t9"></a><table width="75%">
<caption><span>Table 9 Baseline Demographics and Clinical Characteristics Single-Arm Breast Cancer Trial</span></caption>
<col align="left" valign="middle" width="45%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Patients With Measurable Disease<br>(n=135)</th>
<th class="Lrule Rrule" align="center" valign="bottom">All Patients<br>(n=162)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Lung, pleura, liver, peritoneum</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Includes 2 patients treated with an anthracenedione</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">
<span class="Bold Italics">Age</span> (median, years)</td>
<td class="Botrule Lrule" align="center">55</td>
<td class="Botrule Lrule Rrule" align="center">56</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold Italics">Karnofsky PS</span></td>
<td class="Botrule Lrule" align="center">90</td>
<td class="Botrule Lrule Rrule" align="center">90</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">No. Disease Sites</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  1-2</td>
<td class="Lrule" align="center">43 (32%)</td>
<td class="Lrule Rrule" align="center">60 (37%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  3-4</td>
<td class="Lrule" align="center">63 (46%)</td>
<td class="Lrule Rrule" align="center">69 (43%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  &gt;5</td>
<td class="Botrule Lrule" align="center">29 (22%)</td>
<td class="Botrule Lrule Rrule" align="center">34 (21%)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">Dominant Site of Disease</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Visceral<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Lrule" align="center">101 (75%)</td>
<td class="Lrule Rrule" align="center">110 (68%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Soft Tissue</td>
<td class="Lrule" align="center">30 (22%)</td>
<td class="Lrule Rrule" align="center">35 (22%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Bone</td>
<td class="Botrule Lrule" align="center">4 (3%)</td>
<td class="Botrule Lrule Rrule" align="center">17 (10%)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold Italics">Prior Chemotherapy</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Paclitaxel</td>
<td class="Lrule" align="center">135 (100%)</td>
<td class="Lrule Rrule" align="center">162 (100%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Anthracycline<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Lrule" align="center">122 (90%)</td>
<td class="Lrule Rrule" align="center">147 (91%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  5-FU</td>
<td class="Lrule" align="center">110 (81%)</td>
<td class="Lrule Rrule" align="center">133 (82%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Resistance to Paclitaxel</td>
<td class="Lrule" align="center">103 (76%)</td>
<td class="Lrule Rrule" align="center">124 (77%)</td>
</tr>
<tr>
<td class="Lrule" align="left">  Resistance to an Anthracycline<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Lrule" align="center">55 (41%)</td>
<td class="Lrule Rrule" align="center">67 (41%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">  Resistance to both Paclitaxel<br>    and an Anthracycline<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Botrule Lrule" align="center" valign="bottom">43 (32%)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">51 (31%)</td>
</tr>
</tbody>
</table>
<p>Antitumor responses for patients with disease resistant to both paclitaxel and an anthracycline are shown in <span class="Bold"><a href="#t10">Table 10</a></span>.</p>
<a name="t10"></a><table width="75%">
<caption><span>Table 10	Response Rates in Doubly-Resistant Patients Single-Arm Breast Cancer Trial</span></caption>
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="center"></th>
<th class="Lrule Rrule" align="center">Resistance to Both Paclitaxel and an Anthracycline<br>(n=43)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Includes 2 patients treated with an anthracenedione</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>From date of first response</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">CR</td>
<td class="Botrule Lrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">PR<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">11</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">CR + PR<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">11</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Response Rate<a href="#footnote-9" class="Sup">*</a><br>(95% C.I.)</td>
<td class="Botrule Lrule Rrule" align="center">25.6%<br>(13.5, 41.2)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">Duration of Response,<a href="#footnote-9" class="Sup">*</a><br>Median in days<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a><br>(Range)</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">154<br>(63-233)</td>
</tr>
</tbody>
</table>
<p>For the subgroup of 43 patients who were doubly resistant, the median time to progression was 102 days and the median survival was 255 days. The objective response rate in this population was supported by a response rate of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy (see <span class="Bold"><a href="#t9">Table 9</a></span>). The median time to progression was 90 days and the median survival was 306 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Colorectal Cancer</h2>
<ul>
<li>XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither XELODA nor combination chemotherapy prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared to 5-FU/LV. Physicians should consider these results when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer.</li>
<li>XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Breast Cancer</h2>
<ul>
<li>XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.</li>
<li>XELODA monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m<span class="Sup">2</span> of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">XELODA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to capecitabine or to any of its components. XELODA is contraindicated in patients who have a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 5-fluorouracil. XELODA is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. XELODA is also contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance below 30 mL/min [Cockroft and Gault]) (see <span class="Bold"><a href="#C_special">CLINICAL PHARMACOLOGY: Special Populations</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline require dose reduction (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). Patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline should be carefully monitored for adverse events. Prompt interruption of therapy with subsequent dose adjustments is recommended if a patient develops a grade 2 to 4 adverse event as outlined in <span class="Bold"><a href="#t18">Table 18</a></span> in <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></h2>
<p class="First">See <span class="Bold"><a href="#BOXED">Boxed WARNING</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">XELODA can induce <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, sometimes severe. Patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, the median time to first occurrence of grade 2 to 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 34 days (range from 1 to 369 days). The median duration of grade 3 to 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 5 days. National Cancer Institute of Canada (NCIC) grade 2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> as an increase of 7 to 9 stools/day or <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> and <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>, and grade 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> as an increase of ≥10 stools/day or grossly <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> or the need for parenteral support. If grade 2, 3 or 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs, administration of XELODA should be immediately interrupted until the <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolves or decreases in intensity to grade 1. Following a reoccurrence of grade 2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or occurrence of any grade 3 or 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, subsequent doses of XELODA should be decreased (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). Standard antidiarrheal treatments (eg, loperamide) are recommended.</p>
<p><span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">Necrotizing enterocolitis</span> (<span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">typhlitis</span>) has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_geriatric"></a><a name="section-6.4"></a><p></p>
<h2>Geriatric Patients</h2>
<p class="First">Patients ≥80 years old may experience a greater incidence of grade 3 or 4 adverse events (see <span class="Bold"><a href="#P_geriatric">PRECAUTIONS: Geriatric Use</a></span>). In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, 62% of the 21 patients ≥80 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in 6 (28.6%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 3 (14.3%), hand-and-foot syndrome in 3 (14.3%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 2 (9.5%) patients. Among the 10 patients 70 years of age and greater (no patients were &gt;80 years of age) treated with XELODA in combination with docetaxel, 30% (3 out of 10) of patients experienced grade 3 or 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, and 40% (4 out of 10) experienced grade 3 hand-and-foot syndrome.</p>
<p>Among the 67 patients ≥60 years of age receiving XELODA in combination with docetaxel, the incidence of grade 3 or 4 treatment-related adverse events, treatment-related serious adverse events, withdrawals due to adverse events, treatment discontinuations due to adverse events and treatment discontinuations within the first two treatment cycles was higher than in the &lt;60 years of age patient group.</p>
<p>In 995 patients receiving XELODA as adjuvant therapy for Dukes' C colon cancer after resection of the primary tumor, 41% of the 398 patients ≥65 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event: hand-and-foot syndrome in 75 (18.8%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in 52 (13.1%), <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> in 12 (3.0%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> in 11 (2.8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 6 (1.5%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 5 (1.3%) patients. In patients ≥65 years of age (all randomized population; capecitabine 188 patients, 5-FU/LV 208 patients) treated for Dukes' C colon cancer after resection of the primary tumor, the hazard ratios for disease-free survival and overall survival for XELODA compared to 5-FU/LV were 1.01 (95% C.I. 0.80 – 1.27) and 1.04 (95% C.I. 0.79 – 1.37), respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy </h2>
<p class="First">XELODA may cause fetal harm when given to a pregnant woman. Capecitabine at doses of 198 mg/kg/day during organogenesis caused malformations and embryo <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in mice. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.2 times the corresponding values in patients administered the recommended daily dose. Malformations in mice included <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, oligodactyly, <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span>, <span class="product-label-link" type="condition" conceptid="4162283" conceptname="Syndactyly">syndactyly</span>, kinky tail and dilation of cerebral ventricles. At doses of 90 mg/kg/day, capecitabine given to pregnant monkeys during organogenesis caused <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>. This dose produced 5'-DFUR AUC values about 0.6 times the corresponding values in patients administered the recommended daily dose. There are no adequate and well-controlled studies in pregnant women using XELODA. If the drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with XELODA.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Patients receiving therapy with XELODA should be monitored by a physician experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Combination With Other Drugs</h2>
<p class="First">Use of XELODA in combination with irinotecan has not been adequately studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Hand-and-Foot Syndrome</h2>
<p class="First">Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy-induced acral <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>) is a cutaneous toxicity. Median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3 for patients receiving XELODA monotherapy in the metastatic setting. Grade 1 is characterized by any of the following: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>/<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, painless <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the hands and/or feet and/or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which does not disrupt normal activities. Grade 2 hand-and-foot syndrome is defined as painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the hands and/or feet and/or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> affecting the patient's activities of daily living. Grade 3 hand-and-foot syndrome is defined as moist <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, ulceration, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of the hands and/or feet and/or severe <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that causes the patient to be unable to work or perform activities of daily living. If grade 2 or 3 hand-and-foot syndrome occurs, administration of XELODA should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of XELODA should be decreased (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Cardiotoxicity</h2>
<p class="First">The cardiotoxicity observed with XELODA includes <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, electrocardiographic changes, and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. These adverse events may be more common in patients with a prior history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4299531" conceptname="Dihydrouracil dehydrogenase (NADP^+^) deficiency">Dihydropyrimidine Dehydrogenase Deficiency</span></h2>
<p class="First">Rarely, unexpected, severe toxicity (eg, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>) associated with 5-fluorouracil has been attributed to a deficiency of dihydropyrimidine dehydrogenase (DPD) activity. A link between decreased levels of DPD and increased, potentially fatal toxic effects of 5-fluorouracil therefore cannot be excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> should be carefully monitored when XELODA is administered. The effect of severe hepatic dysfunction on the disposition of XELODA is not known (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></h2>
<p class="First">In 875 patients with either metastatic breast or colorectal cancer who received at least one dose of XELODA 1250 mg/m<span class="Sup">2</span> twice daily as monotherapy for 2 weeks followed by a 1-week rest period, grade 3 (1.5-3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 15.2% (n=133) of patients and grade 4 (&gt;3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 3.9% (n=34) of patients. Of 566 patients who had hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline and 309 patients without hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline, grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 22.8% and 12.3%, respectively. Of the 167 patients with grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, 18.6% (n=31) also had postbaseline elevations (grades 1 to 4, without elevations at baseline) in alkaline phosphatase and 27.5% (n=46) had postbaseline elevations in transaminases at any time (not necessarily concurrent). The majority of these patients, 64.5% (n=20) and 71.7% (n=33), had liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline. In addition, 57.5% (n=96) and 35.3% (n=59) of the 167 patients had elevations (grades 1 to 4) at both prebaseline and postbaseline in alkaline phosphatase or transaminases, respectively. Only 7.8% (n=13) and 3.0% (n=5) had grade 3 or 4 elevations in alkaline phosphatase or transaminases.</p>
<p>In the 596 patients treated with XELODA as first-line therapy for metastatic colorectal cancer, the incidence of grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> was similar to the overall clinical trial safety database of XELODA monotherapy. The median time to onset for grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> in the colorectal cancer population was 64 days and median total bilirubin increased from 8 µm/L at baseline to 13 µm/L during treatment with XELODA. Of the 136 colorectal cancer patients with grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, 49 patients had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> as their last measured value, of which 46 had liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> at baseline.</p>
<p>In 251 patients with metastatic breast cancer who received a combination of XELODA and docetaxel, grade 3 (1.5 to 3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 7% (n=17) and grade 4 (&gt;3 × ULN) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> occurred in 2% (n=5).</p>
<p>If drug-related grade 2 to 4 elevations in bilirubin occur, administration of XELODA should be immediately interrupted until the <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> resolves or decreases in intensity to grade 1. NCIC grade 2 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> is defined as 1.5 × normal, grade 3 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> as 1.5 to 3 × normal and grade 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> as &gt;3 × normal. (See recommended dose modifications under <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>Hematologic</h2>
<p class="First">In 875 patients with either metastatic breast or colorectal cancer who received a dose of 1250 mg/m<span class="Sup">2</span> administered twice daily as monotherapy for 2 weeks followed by a 1-week rest period, 3.2%, 1.7%, and 2.4% of patients had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or decreases in hemoglobin, respectively. In 251 patients with metastatic breast cancer who received a dose of XELODA in combination with docetaxel, 68% had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, 2.8% had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and 9.6% had grade 3 or 4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility </h2>
<p class="First">Adequate studies investigating the carcinogenic potential of XELODA have not been conducted. Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). Capecitabine was clastogenic in vitro to human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> but not clastogenic in vivo to mouse bone marrow (micronucleus test). Fluorouracil causes mutations in bacteria and yeast. Fluorouracil also causes chromosomal abnormalities in the mouse micronucleus test in vivo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10"></a><p></p>
<h2>Impairment of Fertility</h2>
<p class="First">In studies of fertility and general reproductive performance in mice, oral capecitabine doses of 760 mg/kg/day disturbed estrus and consequently caused a decrease in fertility. In mice that became pregnant, no fetuses survived this dose. The disturbance in estrus was reversible. In males, this dose caused degenerative changes in the testes, including decreases in the number of spermatocytes and spermatids. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.7 times the corresponding values in patients administered the recommended daily dose.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.11"></a><p></p>
<h2>Information for Patients (see Patient Package Insert) </h2>
<p class="First">Patients and patients' caregivers should be informed of the expected adverse effects of XELODA, particularly <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and hand-and-foot syndrome, and should be made aware that patient-specific dose adaptations during therapy are expected and necessary (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). Patients should be encouraged to recognize the common grade 2 toxicities associated with XELODA treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.12"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (an increase of 4 to 6 stools/day or nocturnal stools) or greater should be instructed to stop taking XELODA immediately. Standard antidiarrheal treatments (eg, loperamide) are recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.13"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </h2>
<p class="First">Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (food intake significantly decreased but able to eat intermittently) or greater should be instructed to stop taking XELODA immediately. Initiation of symptomatic treatment is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2 to 5 episodes in a 24-hour period) or greater should be instructed to stop taking XELODA immediately. Initiation of symptomatic treatment is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.15"></a><p></p>
<h2>Hand-and-Foot Syndrome</h2>
<p class="First">Patients experiencing grade 2 hand-and-foot syndrome (painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the hands and/or feet and/or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> affecting the patients' activities of daily living) or greater should be instructed to stop taking XELODA immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.16"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></h2>
<p class="First">Patients experiencing grade 2 <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (painful <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> of the mouth or tongue, but able to eat) or greater should be instructed to stop taking XELODA immediately. Initiation of symptomatic treatment is recommended (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.17"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">Patients who develop a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of 100.5°F or greater or other evidence of potential <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be instructed to call their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.18"></a><p></p>
<h2>Drug-Food Interaction</h2>
<p class="First">In all clinical trials, patients were instructed to administer XELODA within 30 minutes after a meal. Since current safety and efficacy data are based upon administration with food, it is recommended that XELODA be administered with food (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="P_drug"></a><a name="section-7.19"></a><p></p>
<h2>Drug-Drug Interactions</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.20"></a><p></p>
<h2>Antacid</h2>
<p class="First">The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox) on the pharmacokinetics of XELODA was investigated in 12 cancer patients. There was a small increase in plasma concentrations of XELODA and one metabolite (5'-DFCR); there was no effect on the 3 major metabolites (5'-DFUR, 5-FU and FBAL).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="P_drug_anti"></a><a name="section-7.21"></a><p></p>
<h2>Anticoagulants</h2>
<p class="First">Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) monitored closely with great frequency and the anticoagulant dose should be adjusted accordingly (see <span class="Bold"><a href="#BOXED">Boxed WARNING</a></span> and <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>). Altered coagulation parameters and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within 1 month after stopping XELODA. These events occurred in patients with and without liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC of S-warfarin. The maximum observed INR value increased by 91%. This interaction is probably due to an inhibition of cytochrome P450 2C9 by capecitabine and/or its metabolites (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.22"></a><p></p>
<h2>CYP2C9 substrates</h2>
<p class="First">Other than warfarin, no formal drug-drug interaction studies between XELODA and other CYP2C9 substrates have been conducted. Care should be exercised when XELODA is coadministered with CYP2C9 substrates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.23"></a><p></p>
<h2>Phenytoin</h2>
<p class="First">The level of phenytoin should be carefully monitored in patients taking XELODA and phenytoin dose may need to be reduced (see <span class="Bold"><a href="#D_dose">DOSAGE AND ADMINISTRATION: Dose Management Guidelines</a></span>). Postmarketing reports indicate that some patients receiving XELODA and phenytoin had toxicity associated with elevated phenytoin levels. Formal drug-drug interaction studies with phenytoin have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP2C9 isoenzyme by capecitabine and/or its metabolites (see <span class="Bold"><a href="#P_drug_anti">PRECAUTIONS: Drug-Drug Interactions: Anticoagulants</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.24"></a><p></p>
<h2>Leucovorin</h2>
<p class="First">The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> from severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> have been reported in elderly patients receiving weekly leucovorin and fluorouracil.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.25"></a><p></p>
<h2>Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.26"></a><p></p>
<h2>Teratogenic Effects</h2>
<p class="First">Category D (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>). Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with XELODA.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.27"></a><p></p>
<h2>Nursing Women</h2>
<p class="First">Lactating mice given a single oral dose of capecitabine excreted significant amounts of capecitabine metabolites into the milk. Because of the potential for serious adverse reactions in nursing infants from capecitabine, it is recommended that nursing be discontinued when receiving XELODA therapy.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.28"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of XELODA in persons &lt;18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="P_geriatric"></a><a name="section-7.29"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Physicians should pay particular attention to monitoring the adverse effects of XELODA in the elderly (see <span class="Bold"><a href="#W_geriatric">WARNINGS: Geriatric Patients</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Adjuvant Colon Cancer</h2>
<p class="First"><span class="Bold"><a href="#t11">Table 11</a></span> shows the adverse events occurring in ≥5% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment. A total of 995 patients were treated with 1250 mg/m<span class="Sup">2</span> twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m<span class="Sup">2</span> leucovorin IV followed by 425 mg/m<span class="Sup">2</span> IV bolus 5-FU, on days 1-5, every 28 days). The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients. A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse events. A total of 18 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to XELODA and 10 (1.0%) randomized to 5-FU/LV.</p>
<p><span class="Bold"><a href="#t12">Table 12</a></span> shows grade 3/4 laboratory abnormalities occurring in ≥1% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.</p>
<a name="t11"></a><table width="80%">
<caption><span>Table 11	Percent Incidence of Adverse Events Reported in ≥5% of Patients Treated With XELODA or 5-FU/LV for Colon Cancer in the Adjuvant Setting (Safety Population)</span></caption>
<col align="left" valign="middle" width="24%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center" colspan="4">Adjuvant Treatment for Colon Cancer (N=1969)</th>
</tr>
<tr>
<th class="Lrule Toprule" align="left"></th>
<th class="Lrule Toprule" align="center" colspan="2">XELODA<br>(N=995)</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">5-FU/LV<br>(N=974)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left">Body System/<br>Adverse Event</th>
<th class="Lrule Toprule" align="center" valign="top">All Grades</th>
<th class="Lrule Toprule" align="center" valign="top">Grade 3/4</th>
<th class="Lrule Toprule" align="center" valign="top">All Grades</th>
<th class="Lrule Rrule Toprule" align="center" valign="top">Grade 3/4</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">65</td>
<td class="Rrule" align="center">14</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">60</td>
<td class="Rrule" align="center">14</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center" valign="top">14</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">16</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span></td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">- </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Hand-and-Foot Syndrome</td>
<td class="Rrule" align="center" valign="top">60</td>
<td class="Rrule" align="center" valign="top">17</td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">General Disorders and Administration Site Conditions</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Metabolism and Nutrition Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Blood and Lymphatic System Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Respiratory Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">-</td>
</tr>
</tbody>
</table>
<a name="t12"></a><table width="70%">
<caption><span>Table 12	Percent Incidence of Grade 3/4 Laboratory Abnormalities Reported in ≥1% of Patients Receiving XELODA Monotherapy for Adjuvant Treatment of Colon Cancer (Safety Population)</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="left" rowspan="2" valign="bottom">Adverse Event</th>
<th class="Lrule" align="center">XELODA<br>(n=995)</th>
<th class="Lrule Rrule" align="center">IV 5-FU/LV<br>(n=974)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">Grade 3/4 %</th>
<th class="Lrule Rrule" align="center">Grade 3/4 %</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>The incidence of grade 3/4 <span class="product-label-link" type="condition" conceptid="434008" conceptname="White blood cell disorder">white blood cell abnormalities</span> was 1.3% in the XELODA arm and 4.9% in the IV 5-FU/LV arm.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>It should be noted that grading was according to NCIC CTC Version 1 (May, 1994). In the NCIC-CTC Version 1, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> grade 3 indicates a bilirubin value of 1.5 to 3.0 × upper limit of normal (ULN) range, and grade 4 a value of &gt; 3.0 × ULN.  The NCI CTC Version 2 and above define a grade 3 bilirubin value of &gt;3.0 to 10.0 × ULN, and grade 4 values &gt;10.0 × ULN.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">  Increased ALAT (SGPT)</td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Increased calcium </td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Decreased calcium</td>
<td class="Rrule" align="center">2.3</td>
<td class="Rrule" align="center">2.2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Decreased hemoglobin</span></td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center">1.2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Decreased <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span></td>
<td class="Rrule" align="center">13.0</td>
<td class="Rrule" align="center">13.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Decreased <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">26.2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Decreased <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>/granulocytes</td>
<td class="Rrule" align="center">2.4</td>
<td class="Rrule" align="center">26.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Decreased platelets</td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Increased bilirubin<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>
</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">6.3</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Metastatic Colorectal Cancer</h2>
<p class="First"><span class="Bold"><a href="#t13">Table 13</a></span> shows the adverse events occurring in ≥5% of patients from pooling the two phase 3 trials in first line metastatic colorectal cancer. A total of 596 patients with metastatic colorectal cancer were treated with 1250 mg/m<span class="Sup">2</span> twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m<span class="Sup">2</span> leucovorin IV followed by 425 mg/m<span class="Sup">2</span> IV bolus 5-FU, on days 1-5, every 28 days). In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients. A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse events/intercurrent illness. A total of 82 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to XELODA and 32 (5.4%) randomized to 5-FU/LV.</p>
<a name="t13"></a><table width="85%">
<caption><span>Table 13 Pooled Phase 3 Colorectal Trials: Percent Incidence of Adverse Events in ≥5% of Patients</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<thead>
<tr class="First">
<th class="Lrule" align="left" valign="top">Adverse Event</th>
<th class="Lrule" align="center" colspan="3">XELODA<br>(n=596)</th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">5-FU/LV<br>(n=593)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left"></th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Toprule" align="center">Grade 4<br>%</th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Rrule Toprule" align="center">Grade 4<br>%</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="7">– Not observed</td></tr>
<tr class="Last"><td align="left" colspan="7">NA = Not Applicable</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Bold">Number of Patients With </span><span class="Bold">&gt;</span><span class="Bold"> One Adverse Event</span>
</td>
<td class="Rrule" align="center">96</td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">94</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Body System/Adverse Event</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">GI</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">61</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">62</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4096856" conceptname="Incomplete passage of stool">Gastrointestinal Motility Disorder</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4150136" conceptname="Discomfort in mouth">Oral Discomfort</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Upper GI Inflammatory Disorders</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Skin and Subcutaneous</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Hand-and-Foot Syndrome</td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin Discoloration</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">General</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Neurological</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral Sensory Neuropathy</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Metabolism</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Eye</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision Abnormal</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Respiratory</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31057" conceptname="Disorder of pharynx">Pharyngeal Disorder</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Musculoskeletal</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Vascular</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Psychiatric</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Mood Alteration</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Viral</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Blood and Lymphatic</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">80</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">79</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Hepatobiliary</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Breast Cancer Combination</h2>
<p class="First">The following data are shown for the combination study with XELODA and docetaxel in patients with metastatic breast cancer in <span class="Bold"><a href="#t14">Table 14</a></span> and <span class="Bold"><a href="#t15">Table 15</a></span>. In the XELODA and docetaxel combination arm the treatment was XELODA administered orally 1250 mg/m<span class="Sup">2</span> twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1-hour intravenous infusion at a dose of 75 mg/m<span class="Sup">2</span> on the first day of each 3-week cycle for at least 6 weeks. In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m<span class="Sup">2</span> on the first day of each 3-week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse events. The percentage of patients requiring dose reductions due to adverse events was 65% in the combination arm and 36% in the monotherapy arm. The percentage of patients requiring treatment interruptions due to adverse events in the combination arm was 79%. Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.</p>
<a name="t14"></a><table width="85%">
<caption><span>Table 14	Percent Incidence of Adverse Events Considered Related or Unrelated to Treatment in ≥5% of Patients Participating in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy Study</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<thead>
<tr class="First">
<th class="Lrule" align="left" valign="top">Adverse Event</th>
<th class="Lrule" align="center" colspan="3" valign="top">XELODA 1250 mg/m<span class="Sup">2</span>/bid<br>With Docetaxel<br>75 mg/m<span class="Sup">2</span>/3 weeks</th>
<th class="Lrule Rrule" align="center" colspan="3" valign="top">Docetaxel<br>100 mg/m<span class="Sup">2</span>/3 weeks</th>
</tr>
<tr>
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="3" valign="bottom">(n=251)</th>
<th class="Lrule Rrule" align="center" colspan="3" valign="bottom">(n=255)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left"></th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Toprule" align="center">Grade 4<br>%</th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Rrule Toprule" align="center">Grade 4<br>%</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="7">– Not observed</td></tr>
<tr class="Last"><td align="left" colspan="7">NA = Not Applicable</td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold">Number of Patients With at Least One Adverse Event</span></td>
<td class="Lrule" align="center" valign="bottom">99</td>
<td class="Lrule Rrule" align="center" valign="bottom">76.5</td>
<td class="Rrule" align="center" valign="bottom">29.1</td>
<td align="center" valign="bottom">97</td>
<td class="Lrule Rrule" align="center" valign="bottom">57.6</td>
<td class="Rrule" align="center" valign="bottom">31.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Body System/Adverse Event</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">GI </span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">67</td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Rrule" align="center">&lt;1</td>
<td align="center">48</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Lrule" align="center">67</td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Rrule" align="center">&lt;1</td>
<td align="center">43 </td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule" align="center">45</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
<td align="center">36</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">35</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td align="center">24</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">20</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">18</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Lrule" align="center">30</td>
<td class="Lrule Rrule" align="center">&lt;3</td>
<td class="Rrule" align="center">&lt;1</td>
<td align="center">24</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule" align="center">14</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Lrule" align="center">6</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Skin and Subcutaneous</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Hand-and-Foot Syndrome</td>
<td class="Lrule" align="center">63</td>
<td class="Lrule Rrule" align="center">24</td>
<td class="Rrule" align="center">NA</td>
<td align="center">8 </td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule" align="center">41</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Rrule" align="center">–</td>
<td align="center">42</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span></td>
<td class="Lrule" align="center">14</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">15</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></td>
<td class="Lrule" align="center">8</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">11</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Erythematous</td>
<td class="Lrule" align="center">9</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4006158" conceptname="Leukonychia">Nail Discoloration</span></td>
<td class="Lrule" align="center">6</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">4 </td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">Onycholysis</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule" align="center">4 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">General</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Lrule" align="center">28</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">34</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Lrule" align="center">26</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">&lt;1</td>
<td align="center">25</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">22</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
<td align="center">27</td>
<td class="Lrule Rrule" align="center">6</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td class="Lrule" align="center">16</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">11</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Limb</span></td>
<td class="Lrule" align="center">13</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">13</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Lrule" align="center">7</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">6</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Lrule" align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> (non-cardiac)</td>
<td class="Lrule" align="center">4 </td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">6 </td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like Illness</td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Neurological</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span></td>
<td class="Lrule" align="center">16</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">14</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">15</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">–</td>
<td align="center">15</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Lrule" align="center">12</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">16</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">12</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule" align="center">8</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">10</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></td>
<td class="Lrule" align="center">6</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">10</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoaesthesia</span></td>
<td class="Lrule" align="center">4 </td>
<td class="Lrule Rrule" align="center">&lt;1 </td>
<td class="Rrule" align="center">–</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Metabolism</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule" align="center">13</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td align="center">11</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span></td>
<td class="Lrule" align="center">10</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></td>
<td class="Lrule" align="center">7</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Lrule" align="center">10</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Eye</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation Increased</span></td>
<td class="Lrule" align="center">12</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">4 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">1 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Musculoskeletal</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Lrule" align="center">15</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">24</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule" align="center">15 </td>
<td class="Lrule Rrule" align="center">2 </td>
<td class="Rrule" align="center">–</td>
<td align="center">25</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Lrule" align="center">12</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">11</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span></td>
<td class="Lrule" align="center">8</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">10</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Cardiac</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Lrule" align="center">33</td>
<td class="Lrule Rrule" align="center">&lt;2</td>
<td class="Rrule" align="center">–</td>
<td align="center">34</td>
<td class="Lrule Rrule" align="center">&lt;3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Blood</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Neutropenic Fever</span></td>
<td class="Lrule" align="center">16</td>
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">13</td>
<td align="center">21</td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Respiratory</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule" align="center">14</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
<td align="center">16</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Lrule" align="center">13</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
<td align="center">22</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span></td>
<td class="Lrule" align="center">12</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">–</td>
<td align="center">11</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Lrule" align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">6</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">3 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural Effusion</span></td>
<td class="Lrule" align="center">2 </td>
<td class="Lrule Rrule" align="center">1 </td>
<td class="Rrule" align="center">–</td>
<td align="center">7</td>
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Candidiasis</span></td>
<td class="Lrule" align="center">7</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">8</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></td>
<td class="Lrule" align="center">6</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">4 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  Upper Respiratory Tract</td>
<td class="Lrule" align="center">4 </td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Vascular</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">Lymphoedema</span></td>
<td class="Lrule" align="center">3 </td>
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Psychiatric</span></span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
<td align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Lrule Rrule" align="center">–</td>
</tr>
</tbody>
</table>
<a name="t15"></a><table width="90%">
<caption><span>Table 15	Percent of Patients With Laboratory Abnormalities Participating in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy Study</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<thead>
<tr class="First">
<th class="Lrule" align="left" valign="top">Adverse Event</th>
<th class="Lrule" align="center" colspan="3">XELODA 1250 mg/m<span class="Sup">2</span>/bid<br>With Docetaxel<br>75 mg/m<span class="Sup">2</span>/3 weeks</th>
<th class="Lrule Rrule" align="center" colspan="3" valign="top">Docetaxel<br>100 mg/m<span class="Sup">2</span>/3 weeks</th>
</tr>
<tr>
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="3" valign="bottom">(n=251)</th>
<th class="Lrule Rrule" align="center" colspan="3" valign="bottom">(n=255)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left" valign="top">Body System/Adverse Event</th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Toprule" align="center">Grade 4<br>%</th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Rrule Toprule" align="center">Grade 4<br>%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Hematologic</span></span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule" align="center">91</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">88</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">33</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span></td>
<td class="Lrule Rrule" align="center">86</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">87</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">66</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule" align="center">41</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule" align="center">80</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">83</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphocytopenia</span></td>
<td class="Lrule Rrule" align="center">99</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">98</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">40</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold"><span class="Italics">Hepatobiliary</span></span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></td>
<td class="Lrule Rrule" align="center">20</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Breast Cancer XELODA Monotherapy</h2>
<p class="First">The following data are shown for the study in stage IV breast cancer patients who received a dose of 1250 mg/m<span class="Sup">2</span> administered twice daily for 2 weeks followed by a 1-week rest period. The mean duration of treatment was 114 days. A total of 13 out of 162 patients (8%) discontinued treatment because of adverse events/intercurrent illness.</p>
<a name="t16"></a><table width="80%">
<caption><span>Table 16	Percent Incidence of Adverse Events Considered Remotely, Possibly or Probably Related to Treatment in ≥5% of Patients Participating in the Single Arm Trial in Stage IV Breast Cancer</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule" align="left" valign="top">Adverse Event</th>
<th class="Lrule Rrule" align="center" colspan="3">Phase 2 Trial in Stage IV Breast Cancer<br>(n=162)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left" valign="top">Body System/Adverse Event</th>
<th class="Lrule Toprule" align="center">Total<br>%</th>
<th class="Lrule Toprule" align="center">Grade 3<br>%</th>
<th class="Lrule Rrule Toprule" align="center">Grade 4<br>%</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="4">– Not observed</td></tr>
<tr class="Last"><td align="left" colspan="4">NA = Not Applicable</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">GI</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Skin and Subcutaneous</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Hand-and-Foot Syndrome</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">General</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Limb</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Neurological</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Metabolism</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Eye</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Musculoskeletal</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">–</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Cardiac</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">–</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Blood</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">72</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Rrule" align="center">94</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Italics">Hepatobiliary</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>XELODA and Docetaxel in Combination</h2>
<p class="First">Shown below by body system are the clinically relevant adverse events in &lt;5% of patients in the overall clinical trial safety database of 251 patients (Study Details) reported as related to the administration of XELODA in combination with docetaxel and that were clinically at least remotely relevant. In parentheses is the incidence of grade 3 and 4 occurrences of each adverse event.</p>
<p>It is anticipated that the same types of adverse events observed in the XELODA monotherapy studies may be observed in patients treated with the combination of XELODA plus docetaxel.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> (0.39), <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> (0.39), <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span> (0.39), <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">hemorrhagic diarrhea</span> (0.80)</p>
<p><span class="Italics">Neurological:</span> <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (0.39), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (1.20), <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span> (0.80), <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> (0.39), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (0.39)</p>
<p><span class="Italics">Cardiac:</span> <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (0.39)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>: </span><span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span> (2.39), <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (0.39), <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span> (0.39)</p>
<p><span class="Italics">Blood and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (0.39), <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased (0.39)</p>
<p><span class="Italics">Vascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (1.20), venous <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> (0.39), <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (0.80)</p>
<p><span class="Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (0.39)</p>
<p><span class="Italics">Hepatobiliary:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (0.39), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> (0.39), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (0.39), <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> (0.39), hepatotoxicity (0.39)</p>
<p><span class="Italics">Immune System:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (1.20)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>XELODA Monotherapy Metastatic Breast and Colorectal Cancer</h2>
<p class="First">Shown below by body system are the clinically relevant adverse events in &lt;5% of patients in the overall clinical trial safety database of 875 patients (phase 3 colorectal studies — 596 patients, phase 2 colorectal study — 34 patients, phase 2 breast cancer studies — 245 patients) reported as related to the administration of XELODA and that were clinically at least remotely relevant. In parentheses is the incidence of grade 3 or 4 occurrences of each adverse event.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">proctalgia</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (0.1), <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> (0.1), <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> (0.3), toxic dilation of intestine, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (0.1)</p>
<p><span class="Italics">Skin and Subcutaneous:</span> <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span> (0.1), <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span> (0.1), <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> (0.1), <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4033685" conceptname="Radiation recall syndrome">radiation recall syndrome</span> (0.2)</p>
<p><span class="Italics">General:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (0.2), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (0.1), <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">difficulty in walking</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, chest <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, collapse, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> (0.1), <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, sedation</p>
<p><span class="Italics">Neurological:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (0.5), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (0.1), abnormal coordination, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (0.2), impaired balance</p>
<p><span class="Italics">Metabolism:</span> increased weight, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> (0.4), <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (0.1), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span></p>
<p><span class="Italics">Eye:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (0.1), <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (0.1), <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (0.2), <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> (0.1), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Italics">Cardiac:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (0.1), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> (0.1), <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span> <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span> (1.0), <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> (0.2), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (0.2), <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span> (0.2), <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (0.3), <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (including <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>) (0.2)</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> (0.1), <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> (0.1), <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></p>
<p><span class="Italics">Blood and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (0.2), <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span> (0.1), <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (0.1), <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenia</span> purpura (1.0), <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (0.1)</p>
<p><span class="Italics">Vascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (0.2), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (0.1), <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphoedema</span> (0.1), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (0.2), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span> (0.1)</p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (0.1)</p>
<p><span class="Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (0.6)</p>
<p><span class="Italics">Ear:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Hepatobiliary:</span> <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span> (0.1), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (0.1), <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> (0.1), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span></p>
<p><span class="Italics">Immune System:</span> <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> (0.1)</p>
<p><span class="Italics">Postmarketing: </span><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, lacrimal duct stenosis</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> would include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>. Medical management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for XELODA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low–molecular-weight metabolite of the parent compound.</p>
<p>Single doses of XELODA were not lethal to mice, rats, and monkeys at doses up to 2000 mg/kg (2.4, 4.8, and 9.6 times the recommended human daily dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of XELODA is 1250 mg/m<span class="Sup">2</span> administered orally twice daily (morning and evening; equivalent to 2500 mg/m<span class="Sup">2</span> total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles. XELODA tablets should be swallowed with water within 30 minutes after a meal. In combination with docetaxel, the recommended dose of XELODA is 1250 mg/m<span class="Sup">2</span> twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m<span class="Sup">2</span> as a 1-hour intravenous infusion every 3 weeks. Pre-medication, according to the docetaxel labeling, should be started prior to docetaxel administration for patients receiving the XELODA plus docetaxel combination. <span class="Bold"><a href="#t17">Table 17</a></span> displays the total daily dose by body surface area and the number of tablets to be taken at each dose.</p>
<p>Adjuvant treatment in patients with Dukes' C colon cancer is recommended for a total of 6 months, ie, XELODA 1250 mg/m<span class="Sup">2</span> orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks).</p>
<a name="t17"></a><table width="80%">
<caption><span>Table 17	XELODA Dose Calculation According to Body Surface Area</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="center" colspan="2">Dose Level 1250 mg/m<span class="Sup">2</span><br>Twice a Day</th>
<th class="Lrule Rrule" align="center" colspan="2">Number of Tablets to be Taken at<br>Each Dose (Morning and Evening)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="center">Surface Area<br>(m<span class="Sup">2</span>)</th>
<th class="Lrule Toprule" align="center">Total Daily<br>Dose<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> (mg)</th>
<th class="Lrule Toprule" align="center" valign="top">150 mg</th>
<th class="Lrule Rrule Toprule" align="center" valign="top">500 mg</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Total Daily Dose divided by 2 to allow equal morning and evening doses</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">≤ 1.25 </td>
<td class="Rrule" align="center">3000</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1.26-1.37 </td>
<td class="Rrule" align="center">3300</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1.38-1.51 </td>
<td class="Rrule" align="center">3600</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1.52-1.65 </td>
<td class="Rrule" align="center">4000</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1.66-1.77 </td>
<td class="Rrule" align="center">4300</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1.78-1.91 </td>
<td class="Rrule" align="center">4600</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1.92-2.05 </td>
<td class="Rrule" align="center">5000</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">2.06-2.17 </td>
<td class="Rrule" align="center">5300</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥ 2.18</td>
<td class="Rrule" align="center">5600</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="D_dose"></a><a name="section-10.1"></a><p></p>
<h2>Dose Management Guidelines</h2>
<p class="First">XELODA dosage may need to be individualized to optimize patient management. Patients should be carefully monitored for toxicity and doses of XELODA should be modified as necessary to accommodate individual patient tolerance to treatment (see <span class="Bold"><a href="#C_STUDIES">CLINICAL STUDIES</a></span>). Toxicity due to XELODA administration may be managed by symptomatic treatment, dose interruptions and adjustment of XELODA dose. Once the dose has been reduced it should not be increased at a later time.</p>
<p>The dose of phenytoin and the dose of coumarin-derivative anticoagulants may need to be reduced when either drug is administered concomitantly with XELODA (see <span class="Bold"><a href="#P_drug">PRECAUTIONS: Drug-Drug Interactions</a></span>).</p>
<p>XELODA dose modification scheme as described below (see <span class="Bold"><a href="#t18">Table 18</a></span> and <span class="Bold"><a href="#t19">Table 19</a></span>) is recommended for the management of adverse events. </p>
<a name="t18"></a><table width="100%">
<caption><span>Table 18 XELODA in Combination With Docetaxel Dose Reduction Schedule</span></caption>
<col align="left" valign="top" width="16%">
<col align="left" valign="top" width="28%">
<col align="left" valign="top" width="28%">
<col align="left" valign="top" width="28%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Toxicity<br>NCIC Grades<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Grade 2</th>
<th class="Rrule" align="center">Grade 3</th>
<th class="Rrule" align="center">Grade 4</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>National Cancer Institute of Canada Common Toxicity Criteria were used except for hand-and-foot syndrome (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">1st appearance</td>
<td class="Rrule" align="left">Grade 2 occurring during the 14 days of XELODA treatment: interrupt XELODA treatment until resolved to grade 0-1. Treatment may be resumed during the cycle at the same dose of XELODA. Doses of XELODA missed during a treatment cycle are not to be replaced. Prophylaxis for toxicities should be implemented where possible.<br><br>Grade 2 persisting at the time the next XELODA/docetaxel treatment is due: delay treatment until resolved to grade 0-1, then continue at 100% of the original XELODA and docetaxel dose. Prophylaxis for toxicities should be implemented where possible.</td>
<td class="Rrule" align="left">Grade 3 occurring during the 14 days of XELODA treatment: interrupt the XELODA treatment until resolved to grade 0-1. Treatment may be resumed during the cycle at 75% of the XELODA dose. Doses of XELODA missed during a treatment cycle are not to be replaced. Prophylaxis for toxicities should be implemented where possible.<br><br>Grade 3 persisting at the time the next XELODA/docetaxel treatment is due: delay treatment until resolved to grade 0-1.<br><br>												For patients developing grade 3 toxicity at any time during the treatment cycle, upon resolution to grade 0-1, subsequent treatment cycles should be continued at 75% of the original XELODA dose and at 55 mg/m<span class="Sup">2</span> of docetaxel. Prophylaxis for toxicities should be implemented where possible.</td>
<td class="Rrule" align="left">Discontinue treatment unless treating physician considers it to be in the best interest of the patient to continue with XELODA at 50% of original dose.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">2nd appearance of same toxicity</td>
<td class="Rrule" align="left">Grade 2 occurring during the 14 days of XELODA treatment: interrupt XELODA treatment until resolved to grade 0-1. Treatment may be resumed during the cycle at 75% of original XELODA dose. Doses of XELODA missed during a treatment cycle are not to be replaced. Prophylaxis for toxicities should be implemented where possible.<br><br>Grade 2 persisting at the time the next XELODA/docetaxel treatment is due: delay treatment until resolved to grade 0-1.<br><br>For patients developing 2nd occurrence of grade 2 toxicity at any time during the treatment cycle, upon resolution to grade 0-1, subsequent treatment cycles should be continued at 75% of the original XELODA dose and at 55 mg/m<span class="Sup">2</span> of docetaxel. Prophylaxis for toxicities should be implemented where possible.<br>
</td>
<td class="Rrule" align="left">Grade 3 occurring during the 14 days of XELODA treatment: interrupt the XELODA treatment until resolved to grade 0-1. Treatment may be resumed during the cycle at 50% of the XELODA dose. Doses of XELODA missed during a treatment cycle are not to be replaced. Prophylaxis for toxicities should be implemented where possible.<br> <br>Grade 3 persisting at the time the next XELODA/docetaxel treatment is due: delay treatment until resolved to grade 0-1.<br> <br>For patients developing grade 3 toxicity at any time during the treatment cycle, upon resolution to grade 0-1, subsequent treatment cycles should be continued at 50% of the original XELODA dose and the docetaxel discontinued. Prophylaxis for toxicities should be implemented where possible.<br>
</td>
<td class="Rrule" align="left">Discontinue treatment.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">3rd appearance of same toxicity</td>
<td class="Rrule" align="left">Grade 2 occurring during the 14 days of XELODA treatment: interrupt XELODA treatment until resolved to grade 0-1. Treatment may be resumed during the cycle at 50% of the original XELODA dose. Doses of XELODA missed during a treatment cycle are not to be replaced. Prophylaxis for toxicities should be implemented where possible.<br> <br>Grade 2 persisting at the time the next XELODA/docetaxel treatment is due: delay treatment until resolved to grade 0-1.<br> <br>For patients developing 3rd occurrence of grade 2 toxicity at any time during the treatment cycle, upon resolution to grade 0-1, subsequent treatment cycles should be continued at 50% of the original XELODA dose and the docetaxel discontinued. Prophylaxis for toxicities should be implemented where possible.</td>
<td class="Rrule" align="left">Discontinue treatment.</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">4th appearance of same toxicity</td>
<td class="Rrule" align="left">Discontinue treatment.</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<p>Dose modification for the use of XELODA as monotherapy is shown in <span class="Bold"><a href="#t19">Table 19</a></span>.</p>
<a name="t19"></a><table width="75%">
<caption><span>Table 19 Recommended Dose Modifications With XELODA Monotherapy</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="45%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Toxicity<br> NCIC Grades<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</th>
<th class="Rrule" align="center" valign="bottom">During a Course of Therapy</th>
<th class="Rrule" align="center">Dose Adjustment for Next Treatment (% of starting dose)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>National Cancer Institute of Canada Common Toxicity Criteria were used except for the hand-and-foot syndrome (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">•    <span class="Italics">Grade 1</span>
</td>
<td class="Rrule" align="center">Maintain dose level</td>
<td class="Rrule" align="center">Maintain dose level</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">•    <span class="Italics">Grade 2</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-1<span class="Sup">st</span> appearance</td>
<td class="Rrule" align="center">Interrupt until resolved to grade 0-1</td>
<td class="Rrule" align="center">100%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-2nd appearance</td>
<td class="Rrule" align="center">Interrupt until resolved to grade 0-1</td>
<td class="Rrule" align="center">75%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-3rd appearance</td>
<td class="Rrule" align="center">Interrupt until resolved to grade 0-1</td>
<td class="Rrule" align="center">50%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-4<span class="Sup">th</span> appearance</td>
<td class="Rrule" align="center">Discontinue treatment permanently</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">•    <span class="Italics">Grade 3</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-1<span class="Sup">st</span> appearance</td>
<td class="Rrule" align="center">Interrupt until resolved to grade 0-1</td>
<td class="Rrule" align="center">75%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-2nd appearance</td>
<td class="Rrule" align="center">Interrupt until resolved to grade 0-1</td>
<td class="Rrule" align="center">50%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">-3rd appearance</td>
<td class="Rrule" align="center">Discontinue treatment permanently</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">•    <span class="Italics">Grade 4</span>
</td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">-1<span class="Sup">st</span> appearance</td>
<td class="Rrule" align="center">Discontinue permanently<br><span class="Italics">OR</span><br>If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1</td>
<td class="Rrule" align="center">50%</td>
</tr>
</tbody>
</table>
<p>Dosage modifications are not recommended for grade 1 events. Therapy with XELODA should be interrupted upon the occurrence of a grade 2 or 3 adverse experience. Once the adverse event has resolved or decreased in intensity to grade 1, then XELODA therapy may be restarted at full dose or as adjusted according to <span class="Bold"><a href="#t18">Table 18</a></span> and <span class="Bold"><a href="#t19">Table 19</a></span>. If a grade 4 experience occurs, therapy should be discontinued or interrupted until resolved or decreased to grade 1, and therapy should be restarted at 50% of the original dose. Doses of XELODA omitted for toxicity are not replaced or restored; instead the patient should resume the planned treatment cycles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Adjustment of Starting Dose in Special Populations</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In patients with mild to moderate hepatic dysfunction due to liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, no starting dose adjustment is necessary; however, patients should be carefully monitored. Patients with severe hepatic dysfunction have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No adjustment to the starting dose of XELODA is recommended in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance = 51 to 80 mL/min [Cockroft and Gault, as shown below]). In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (baseline creatinine clearance = 30 to 50 mL/min), a dose reduction to 75% of the XELODA starting dose when used as monotherapy or in combination with docetaxel (from 1250 mg/m<span class="Sup">2</span> to 950 mg/m<span class="Sup">2</span> twice daily) is recommended (see <span class="Bold"><a href="#C_special">CLINICAL PHARMACOLOGY: Special Populations</a></span>). Subsequent dose adjustment is recommended as outlined in <span class="Bold"><a href="#t18">Table 18</a></span> and <span class="Bold"><a href="#t19">Table 19</a></span> if a patient develops a grade 2 to 4 adverse event (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>). The starting dose adjustment recommendations for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> apply both to XELODA monotherapy and XELODA in combination use with docetaxel.</p>
<p>Cockroft and Gault Equation:</p>
<p>                                                     (140 - age [yrs]) (body wt [kg])</p>
<p>Creatinine clearance for males = —————————————</p>
<p>                                                     (72) (serum creatinine [mg/dL])</p>
<p>Creatinine clearance for females = 0.85 × male value</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Geriatrics</h2>
<p class="First">Physicians should exercise caution in monitoring the effects of XELODA in the elderly. Insufficient data are available to provide a dosage recommendation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HS"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">XELODA is supplied as biconvex, oblong film-coated tablets, available in bottles as follows:</p>
<p><span class="Bold">150 mg</span></p>
<p>color:         light peach<br>engraving:   XELODA on one side, 150 on the other</p>
<p><span class="Bold">500 mg</span></p>
<p>color:         peach<br>engraving:   XELODA on one side, 500 on the other </p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0411-1</td>
<td align="center">500 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">light peach</td>
<td align="center">0004-1101</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Storage Conditions</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. KEEP TIGHTLY CLOSED.</p>
<p>For full Taxotere prescribing information, please refer to Taxotere Package Insert.</p>
<p>This product was Manufactured By:<br>Hoffmann-La Roche Inc.<br>
340 Kingsland Street<br>
Nutley, NJ 07110</p>
<p><span class="Bold"></span><br></p>
<p>And Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-12"></a><p></p>
<h1>PATIENT INFORMATION (TEXT ONLY)</h1>
<p class="First">Read this leaflet before you start taking XELODA<span class="Sup">®</span> [zeh-LOE-duh] and each time you refill your prescription in case the information has changed. This leaflet contains important information about XELODA. However, this information does not take the place of talking with your doctor. This information cannot cover all possible risks and benefits of XELODA. Your doctor should always be your first choice for discussing your medical condition and this medicine.</p>
<p><span class="Bold">What is XELODA?</span></p>
<p>XELODA is a medicine you take by mouth (orally). XELODA is changed in the body to 5-fluorouracil (5-FU). In some patients with colon, rectum or breast cancer, 5-FU stops cancer cells from growing and decreases the size of the tumor.</p>
<p> XELODA is used to treat:</p>
<dl>
<dt>–</dt>
<dd>cancer of the colon after surgery</dd>
<dt>–</dt>
<dd>cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic colorectal cancer). You should know that in studies, other medicines showed improved survival when they were taken together with 5-FU and leucovorin. In studies, XELODA was no worse than 5-FU and leucovorin taken together but did not improve survival compared to these two medicines.</dd>
<dt>–</dt>
<dd>breast cancer that has spread to other parts of the body (metastatic breast cancer) together with another medicine called docetaxel (Taxotere<span class="Sup">®</span>)</dd>
<dt>–</dt>
<dd>breast cancer that has spread to other parts of the body and has not improved after treatment with other medicines such as paclitaxel (Taxol<span class="Sup">®</span>) and anthracycline-containing medicine such as Adriamycin<span class="Sup">™</span> and doxorubicin</dd>
</dl>
<p><span class="Bold">What is the most important information about XELODA?</span></p>
<p>XELODA may increase the effect of other medicines used to thin your blood such as warfarin (Coumadin<span class="Sup">®</span>). It is very important that your doctor knows if you are taking a blood thinner such as warfarin because XELODA may increase the effect of this medicine and could lead to serious side effects. If you are taking blood thinners and XELODA, your doctor needs to check more often how fast your blood clots and change the dose of the blood thinner, if needed.</p>
<p><span class="Bold">Who should not take XELODA?</span></p>
<p><span class="Bold">1. DO NOT TAKE XELODA IF YOU</span></p>
<dl>
<dt>–</dt>
<dd>are nursing a baby. Tell your doctor if you are nursing. XELODA may pass to the baby in your milk and harm the baby.</dd>
<dt>–</dt>
<dd>are allergic to 5-fluorouracil</dd>
<dt>–</dt>
<dd>are allergic to capecitabine or to any of the ingredients in XELODA</dd>
<dt>–</dt>
<dd>have been told that you lack the enzyme DPD (dihydropyrimidine dehydrogenase)</dd>
</dl>
<p><span class="Bold">2. TELL YOUR DOCTOR IF YOU</span></p>
<dl>
<dt>–</dt>
<dd>take a blood thinner such as warfarin (Coumadin). This is very important because XELODA may increase the effect of the blood thinner. If you are taking blood thinners and XELODA, your doctor needs to check more often how fast your blood clots and change the dose of the blood thinner, if needed.</dd>
<dt>–</dt>
<dd>take phenytoin (Dilantin<span class="Sup">®</span>). Your doctor needs to test the levels of phenytoin in your blood more often or change your dose of phenytoin.</dd>
<dt>–</dt>
<dd>are pregnant or think you may be pregnant. XELODA may harm your unborn child. </dd>
<dt>–</dt>
<dd>have kidney problems. Your doctor may prescribe a different medicine or lower the XELODA dose.</dd>
<dt>–</dt>
<dd>have liver problems. You may need to be checked for liver problems while you take XELODA.</dd>
<dt>–</dt>
<dd>have heart problems because you could have more side effects related to your heart.</dd>
<dt>–</dt>
<dd>take the vitamin folic acid. It may affect how XELODA works.</dd>
</dl>
<p><span class="Bold">How should I take XELODA?</span></p>
<p>Take XELODA exactly as your doctor tells you to. Your doctor will prescribe a dose and treatment plan that is right for <span class="Italics">you</span>. Your doctor may want you to take both 150 mg and 500 mg tablets together for each dose. If so, you must be able to identify the tablets. Taking the wrong tablets could cause an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (too much medicine) or underdose (too little medicine). The 150 mg tablets are light peach in color with 150 on one side. The 500 mg tablets are peach in color with 500 on one side. Your doctor may change the amount of medicine you take during your treatment. Your doctor may prescribe XELODA Tablets with Taxotere or docetaxel injection.</p>
<dl>
<dt>–</dt>
<dd>XELODA is taken in 2 daily doses, a morning dose and an evening dose</dd>
<dt>–</dt>
<dd>Take XELODA tablets <span class="Bold">within</span> <span class="Bold">30 minutes after the end of a meal</span> (breakfast and dinner)</dd>
<dt>–</dt>
<dd><span class="Bold">Swallow XELODA tablets with water</span></dd>
<dt>–</dt>
<dd>If you miss a dose of XELODA, do <span class="Underline">not</span> take the missed dose at all and do <span class="Underline">not</span> double the next dose. Instead, continue your regular dosing schedule and check with your doctor.</dd>
<dt>–</dt>
<dd>XELODA is usually taken for 14 days followed by a 7-day rest period (no drug), for a 21-day cycle. Your doctor will tell you how many cycles of treatment you will need.</dd>
<dt>–</dt>
<dd>If you take too much XELODA, contact your doctor or local poison control center or emergency room <span class="Bold">right away</span>.</dd>
</dl>
<p><span class="Bold">What should I avoid while taking XELODA?</span></p>
<dl>
<dt>–</dt>
<dd>Women should not become pregnant while taking XELODA. XELODA may harm your unborn child. Use effective birth control while taking XELODA. Tell your doctor if you become pregnant.</dd>
<dt>–</dt>
<dd>Do not breast-feed. XELODA may pass through your milk and harm your baby.</dd>
<dt>–</dt>
<dd>Men should use birth control while taking XELODA</dd>
</dl>
<p><span class="Bold">What are the most common side effects of XELODA?</span></p>
<p>The most common side effects of XELODA are:</p>
<dl>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sores in the mouth and throat (<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>), stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, loss of appetite, and too much water loss from the body (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>). These side effects are more common in patients age 80 and older.</dd>
<dt>–</dt>
<dd>hand-and-foot syndrome (palms of the hands or soles of the feet tingle, become numb, painful, swollen or red), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, dry, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> or discolored skin, nail problems, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></dd>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (including chest, back, joint, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>), trouble sleeping, and taste problems</dd>
</dl>
<p>These side effects may differ when taking XELODA with Taxotere. Please consult your doctor for possible side effects that may be caused by taking XELODA with Taxotere.</p>
<p>If you are concerned about these or any other side effects while taking XELODA, talk to your doctor.</p>
<p><span class="Bold">Stop taking XELODA immediately and contact your doctor right away</span> if you have the side effects listed below, or other side effects that concern you. Your doctor can then adjust XELODA to a dose that is right for you or stop your XELODA treatment for a while. This should help to reduce the side effects and stop them from getting worse.</p>
<dl>
<dt>–</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:</span></span> if you have an additional 4 bowel movements each day beyond what is normal or any <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> at night</dd>
<dt>–</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>:</span></span> if you vomit more than once in a 24-hour time period</dd>
<dt>–</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>:</span></span> if you lose your appetite, and the amount of food you eat each day is much less than usual</dd>
<dt>–</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>:</span></span> if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or sores in your mouth</dd>
<dt>–</dt>
<dd>
<span class="Bold"><span class="Italics">Hand-and-Foot Syndrome:</span></span> if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of your hands or feet that prevents normal activity</dd>
<dt>–</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span></span> if you have a temperature of 100.5°F or greater, or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
</dl>
<p>Your doctor may tell you to lower the dose or to stop XELODA treatment for a while. If caught early, most of these side effects usually improve after you stop taking XELODA. If they do not improve within 2 to 3 days, call your doctor again. After your side effects have improved, your doctor will tell you whether to start taking XELODA again and what dose to take. Adjusting the dose of XELODA to be right for each patient is an important part of treatment.</p>
<p><span class="Bold">How should I store and use XELODA?</span></p>
<dl>
<dt>–</dt>
<dd>Never share XELODA with anyone</dd>
<dt>–</dt>
<dd>Store XELODA at normal room temperature (about 65° to 85°F)</dd>
<dt>–</dt>
<dd>Keep XELODA and all other medicines out of the reach of children</dd>
<dt>–</dt>
<dd>If you take too much XELODA by mistake, contact your doctor or local poison control center or emergency room <span class="Bold">right away</span>
</dd>
</dl>
<p><span class="Bold">General advice about prescription medicines:</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use XELODA for a condition for which it was not prescribed. Do not give XELODA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about XELODA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about XELODA that is written for health professionals.</p>
<p>XELODA is a registered trademark of Hoffmann – La Roche Inc.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-13"></a><p></p>
<h1>Patient Information</h1>
<p class="First"><span class="Bold">XELODA<span class="Sup">®</span> (capecitabine) TABLETS</span></p>
<p>Read this leaflet before you start taking XELODA<span class="Sup">®</span> [zeh-LOE-duh] and each time you refill your prescription in case the information has changed. This leaflet contains important information about XELODA. However, this information does not take the place of talking with your doctor. This information cannot cover all possible risks and benefits of XELODA. Your doctor should always be your first choice for discussing your medical condition and this medicine.</p>
<p><span class="Bold">What is XELODA?</span></p>
<p>XELODA is a medicine you take by mouth (orally). XELODA is changed in the body to 5-fluorouracil (5-FU). In some patients with colon, rectum or breast cancer, 5-FU stops cancer cells from growing and decreases the size of the tumor.</p>
<p> XELODA is used to treat:</p>
<dl>
<dt>–</dt>
<dd>cancer of the colon after surgery</dd>
<dt>–</dt>
<dd>cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic colorectal cancer). You should know that in studies, other medicines showed improved survival when they were taken together with 5-FU and leucovorin. In studies, XELODA was no worse than 5-FU and leucovorin taken together but did not improve survival compared to these two medicines. </dd>
<dt>–</dt>
<dd>breast cancer that has spread to other parts of the body (metastatic breast cancer) together with another medicine called docetaxel (Taxotere<span class="Sup">®</span>)</dd>
<dt>–</dt>
<dd>breast cancer that has spread to other parts of the body and has not improved after treatment with other medicines such as paclitaxel (Taxol<span class="Sup">®</span>) and anthracycline-containing medicine such as Adriamycin™ and doxorubicin</dd>
</dl>
<p><span class="Bold">What is the most important information about XELODA?</span></p>
<p>XELODA may increase the effect of other medicines used to thin your blood such as warfarin (Coumadin<span class="Sup">®</span>). It is very important that your doctor knows if you are taking a blood thinner such as warfarin because XELODA may increase the effect of this medicine and could lead to serious side effects. If you are taking blood thinners and XELODA, your doctor needs to check more often how fast your blood clots and change the dose of the blood thinner, if needed.</p>
<p><span class="Bold">Who should not take XELODA?</span></p>
<p><span class="Bold">1.	DO NOT TAKE XELODA IF YOU</span></p>
<dl>
<dt>–</dt>
<dd>are nursing a baby. Tell your doctor if you are nursing. XELODA may pass to the baby in your milk and harm the baby.</dd>
<dt>–</dt>
<dd>are allergic to 5-fluorouracil</dd>
<dt>–</dt>
<dd>are allergic to capecitabine or to any of the ingredients in XELODA</dd>
<dt>–</dt>
<dd>have been told that you lack the enzyme DPD (dihydropyrimidine dehydrogenase)</dd>
</dl>
<p><span class="Bold">2.	TELL YOUR DOCTOR IF YOU</span></p>
<dl>
<dt>–</dt>
<dd>take a blood thinner such as warfarin (Coumadin). This is very important because XELODA may increase the effect of the blood thinner. If you are taking blood thinners and XELODA, your doctor needs to check more often how fast your blood clots and change the dose of the blood thinner, if needed.</dd>
<dt>–</dt>
<dd>take phenytoin (Dilantin<span class="Sup">®</span>). Your doctor needs to test the levels of phenytoin in your blood more often or change your dose of phenytoin.</dd>
<dt>–</dt>
<dd>are pregnant or think you may be pregnant. XELODA may harm your unborn child. </dd>
<dt>–</dt>
<dd>have kidney problems. Your doctor may prescribe a different medicine or lower the XELODA dose.</dd>
<dt>–</dt>
<dd>have liver problems. You may need to be checked for liver problems while you take XELODA.</dd>
<dt>–</dt>
<dd>have heart problems because you could have more side effects related to your heart. </dd>
<dt>–</dt>
<dd>take the vitamin folic acid. It may affect how XELODA works.</dd>
</dl>
<p><span class="Bold">How should I take XELODA?</span></p>
<p>Take XELODA exactly as your doctor tells you to. Your doctor will prescribe a dose and treatment plan that is right for <span class="Italics">you</span>. Your doctor may want you to take both 150 mg and 500 mg tablets together for each dose. If so, you must be able to identify the tablets. Taking the wrong tablets could cause an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (too much medicine) or underdose (too little medicine). The 150 mg tablets are light peach in color with 150 on one side. The 500 mg tablets are peach in color with 500 on one side. Your doctor may change the amount of medicine you take during your treatment. Your doctor may prescribe XELODA Tablets with Taxotere or docetaxel injection.</p>
<dl>
<dt>–</dt>
<dd>XELODA is taken in 2 daily doses, a morning dose and an evening dose</dd>
<dt>–</dt>
<dd>Take XELODA tablets <span class="Bold">within 30 minutes after the end of a meal</span> (breakfast and dinner)</dd>
<dt>–</dt>
<dd><span class="Bold">Swallow XELODA tablets with water</span></dd>
<dt>–</dt>
<dd>If you miss a dose of XELODA, do <span class="Underline">not</span> take the missed dose at all and do <span class="Underline">not</span> double the next dose. Instead, continue your regular dosing schedule and check with your doctor.</dd>
<dt>–</dt>
<dd>XELODA is usually taken for 14 days followed by a 7-day rest period (no drug), for a 21-day cycle. Your doctor will tell you how many cycles of treatment you will need.</dd>
<dt>–</dt>
<dd>If you take too much XELODA, contact your doctor or local poison control center or emergency room <span class="Bold">right away</span>.</dd>
</dl>
<p><span class="Bold">What should I avoid while taking XELODA?</span></p>
<dl>
<dt>–</dt>
<dd>Women should not become pregnant while taking XELODA. XELODA may harm your unborn child. Use effective birth control while taking XELODA. Tell your doctor if you become pregnant.</dd>
<dt>–</dt>
<dd>Do not breast-feed. XELODA may pass through your milk and harm your baby.</dd>
<dt>–</dt>
<dd>Men should use birth control while taking XELODA</dd>
</dl>
<p><span class="Bold">What are the most common side effects of XELODA?</span></p>
<p>The most common side effects of XELODA are:</p>
<dl>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sores in the mouth and throat (<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>), stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, loss of appetite, and too much water loss from the body (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>). These side effects are more common in patients age 80 and older.</dd>
<dt>–</dt>
<dd>hand-and-foot syndrome (palms of the hands or soles of the feet tingle, become numb, painful, swollen or red), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, dry, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> or discolored skin, nail problems, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></dd>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (including chest, back, joint, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>), trouble sleeping, and taste problems</dd>
</dl>
<p>These side effects may differ when taking XELODA with Taxotere. Please consult your doctor for possible side effects that may be caused by taking XELODA with Taxotere.</p>
<p>If you are concerned about these or any other side effects while taking XELODA, talk to your doctor.</p>
<p><span class="Bold">Stop taking XELODA immediately and contact your doctor right away</span> if you have the side effects listed below, or other side effects that concern you. Your doctor can then adjust XELODA to a dose that is right for you or stop your XELODA treatment for a while. This should help to reduce the side effects and stop them from getting worse.</p>
<dl>
<dt>–</dt>
<dd>
<span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:</span> if you have an additional 4 bowel movements each day beyond what is normal or any <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> at night</dd>
<dt>–</dt>
<dd>
<span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>:</span> if you vomit more than once in a 24-hour time period</dd>
<dt>–</dt>
<dd>
<span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>:</span> if you lose your appetite, and the amount of food you eat each day is much less than usual</dd>
<dt>–</dt>
<dd>
<span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>:</span> if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or sores in your mouth</dd>
<dt>–</dt>
<dd>
<span class="Bold Italics">Hand-and-Foot Syndrome:</span> if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of your hands or feet that prevents normal activity</dd>
<dt>–</dt>
<dd>
<span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> if you have a temperature of 100.5°F or greater, or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
</dl>
<p>Your doctor may tell you to lower the dose or to stop XELODA treatment for a while. If caught early, most of these side effects usually improve after you stop taking XELODA. If they do not improve within 2 to 3 days, call your doctor again. After your side effects have improved, your doctor will tell you whether to start taking XELODA again and what dose to take. Adjusting the dose of XELODA to be right for each patient is an important part of treatment.</p>
<p><span class="Bold">How should I store and use XELODA?</span></p>
<dl>
<dt>–</dt>
<dd>Never share XELODA with anyone</dd>
<dt>–</dt>
<dd>Store XELODA at normal room temperature (about 65° to 85°F)</dd>
<dt>–</dt>
<dd>Keep XELODA and all other medicines out of the reach of children</dd>
<dt>–</dt>
<dd>If you take too much XELODA by mistake, contact your doctor or local poison control center or emergency room <span class="Bold">right away </span>
</dd>
</dl>
<p><span class="Bold">General advice about prescription medicines:</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use XELODA for a condition for which it was not prescribed. Do not give XELODA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about XELODA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about XELODA that is written for health professionals.</p>
<p>XELODA is a registered trademark of Hoffmann – La Roche Inc.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=xeloda-07.jpg"></p>
<p>Representative sample of labeling (see the <a href="#HS">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Tablet Label</h1>
<p class="First">NDC 53808-0411-1</p>
<p><span class="Bold">Xeloda</span><span class="Sup">®</span><br>(capecitabine)<br>Tablets</p>
<p><span class="Bold">500 mg</span></p>
<p>Each tablet contains<br>500 mg capecitabine.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a732b303-9bbd-42ba-a7c5-61c21629ba93&amp;name=Xeloda%20500mg(Roche).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XELODA 		
					</strong><br><span class="contentTableReg">capecitabine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0411(NDC:0004-1101)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAPECITABINE</strong> (capecitabine) </td>
<td class="formItem">CAPECITABINE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (light peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XELODA;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0411-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020896</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>15601703-7442-48f3-89f4-44fef66b7514</div>
<div>Set id: a732b303-9bbd-42ba-a7c5-61c21629ba93</div>
<div>Version: 1</div>
<div>Effective Time: 20100520</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
